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STUDY OF REGULATED CELL DEATH IN TWO SYSTEMS：
PD-1 IN NATURAL KILLER CELLS AND RIP3 IN NEURONS
Yu Huang, B.S.
Advisory Professor: Dr. Michael Xi Zhu, Ph.D
Cell death is not only an essential phenomenon in normal development and
homeostasis, but also crucial in various pathologies. It is now clear that many types of
cell death can be regulated by pharmacological or genetic interventions. These were
largely achieved by identifying the molecular mechanisms underlying the regulated cell
death (RCD). While in the immune system, RCD needs to be facilitated to help the
clearance of pathogens and tumors, in healthy cells, especially the terminally
differentiated neurons in the nervous system, it is more desirable to protect cells from
dying due to stress under pathological conditions. Thus, understating the inhibitory and
the activating signals for RCD in different systems is important. In this thesis, I will
discuss the study of two key molecules involved in RCD: programmed death 1 (PD-1,
as inhibitor for RCD) and receptor-interacting serine/threonine-protein kinase 3 (RIP3,
as promoter for RCD) in two different systems.
First, I studied the role of PD-1 signaling in the cytotoxicity of natural killer (NK)
cells. In recent years, PD-1 has become a hot target of immunotherapy. However,
because most studies on PD-1 have focused on T cells, the precise mechanism by
which PD-1 mediates its effects on NK cells remains poorly characterized. Using NK
cell lines that express PD-1, I found that PD-1 activation blocked NK cell cytotoxicity.
However, PD-1 signaling did not inhibit cell-cell conjugation between NK and target
vi

cells as NK cells that expressed PD-1 formed stable immunological synapse (IS) with
target cells that expressed the PD-1 ligand, PD-L1. Instead, the PD-1 engagement by
PD-L1 blocked lytic granule (LG) polarization via disruption of the integrin ‘outside-in’
signaling pathway and abolished the calcium signaling for degranulation. Similar to T
cells, the immunoreceptor tyrosine-based switch motif (ITSM) but not immunoreceptor
tyrosine-based inhibitory motif (ITIM) of PD-1 was crucial for its inhibitory effect on
cytotoxicity.
In the second part, I examined the involvement of RIP3 in acidosis-induced cell
death, which critically contributes to ischemic brain injury and was recently shown to
occur through necroptosis, a new form of programmed necrosis. Although RIP3 has
been proven to be an important mediator of necroptosis, whether acidosis-induced
neuronal death requires RIP3 is not clear. Here, I show that RIP3 is required for
acidosis-induced cell death, in which serum starvation is another critical contributing
factor. There are at least two key downstream molecules of RIP3 for
acidosis/starvation-induced

cell

death:

mixed

lineage

kinase

domain-like

pseudokinase (MLKL) and mitochondrial apoptosis-inducing factor (AIF). Inhibiting
RIP3 by an FDA approved anti-cancer drug, dabrafenib, reduced both acid-induced
death of mouse cortical neurons in vitro and brain infarction in mice subjected to middle
cerebral artery occlusion (MCAO) in vivo.
Depending on the specific scenarios and the physiological systems involved,
the goals for pharmacological and/or genetic modification of RCD can be quite different.
Thus, a better understanding of both the positive (e.g., RIP3) and negative (e.g., PDvii

1) regulators of RCD is of significant values for both basic sciences and therapeutic
development in treating different diseases in the future.
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Chapter 1

Introduction
Cell death is the event when a cell ceases to carry out its function. It occurs
naturally as old cells are replaced by new ones, or it may result from stress due to
disease or injury. Due to technical limitations, the early classifications of cell death were
purely based on morphological changes. For a long time, apoptosis, necrosis and
autophagic cell death were considered to be the three main kinds of cell death.
However, with recent improvements in knowledge and research tools, more forms of
cell death have been uncovered, for example, necroptosis parthanatos, anoikis,
entosis and so on. Cells die by a variety of mechanisms; a cell death nomenclature will
be considered useful only if it predicts the possibilities to modulate (induce or inhibit)
cell death. Thus, the Nomenclature Committee on Cell Death (NCCD) recently
suggested a new way to classify cell death based on two major categories (Figure 1).
In the first kind, cells exposed to extreme physicochemical or mechanical stimuli can
die in an uncontrollable manner; such an unavoidable cellular demise is referred to as
“accidental cell death” (ACD). In the second kind, which applies to most settings, cell
death is initiated by a genetically encoded apparatus and its course can be altered by
pharmacological or genetic interventions; this is now referred to as “regulated cell
death” (RCD) (1).
For RCD, on one hand, it is necessary for the body to replace or destroy the old,
malfunctional or sick cells. This is achieved by promoting them to undergo
-1-

programmed death or recruiting other cells such as phagocytes and lymphocytes to
kill them. On the other hand, it is desirable to prevent the loss of healthy or functional
cells such as neurons. For this purpose, the body has developed multiple adaptive
mechanisms to detect and respond to environmental danger and whereby protect the
cells from being damaged.

Figure 1. Cell death classification recommended by NCCD. Cell death can be classified to
ACD and RCD based on whether or not it can be altered by pharmacological or genetic
interventions. The “immune responses” and “necroptosis” labeled in red are the subjects studied
and reported in this thesis.

Cancer cells develop many ways to avoid death by either upregulating proteins
that inhibit death or downregulating those that play important roles in mediating cell
death. The two excellent examples are pathways that involve PD-1 and RIP3. While
PD-1 is an inhibitor of RCD (Figure 2), RIP3 directly mediates RCD (Figure 3). In
studies described in this thesis, I have examined the role and mechanism of PD-1 in
-2-

cytotoxic killing by natural killer (NK) cells and the function and signaling pathways by
which RIP3 contributes to acidosis-induced cell death.

Figure 2. Schematic model of cell death inhibition by PD-1. In the absence of PD-1/PD-L1
engagement (left), NK cell destroys an encountered target cell. However, in the presence of PD1/PD-L1 engagement (right), which triggers inhibitory signaling, the cytotoxicity of NK cell is
suppressed, resulting in the survival of the target cell.

Figure 3. Schematic model of acidotoxic cell death mediated by RIP3. Tissue acidosis
occurs in both cancers and nervous system diseases, such as brain ischemia, trauma, seizure,
Alzheimer's disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). In
neurons, RIP3 mediates cell death in response to acidosis, whereas in many cancer cells, the
expression of RIP3 is suppressed, allowing them to thrive in acidic environment.
-3-

Chapter 2

PD-1 Blocks Lytic Granule Polarization and Calcium signaling

in Natural Killer Cell
This chapter is based upon “Huang Y, Jang JH, Bertolet G, Kang X, Huang SJ,
Hu Q, Qin LD, Zhu MX, Liu DF. PD-1 blocks lytic granule polarization in natural killer
cell immunological synapse via impairing integrin ‘outside-in’ signaling”, currently
under revision for the Journal of Allergy and Clinical Immunololgy.

2.1 Background
2.1.1 NK cells in immune system
NK cells provide the first line of defense to cancer and virus infection (2, 3).
These cells can migrate into almost any tissue triggered by inflammation and other
factors (4). Traditionally, NK cells are considered to be innate immune cells since they
do not rearrange genes to acquire antigen-specific receptors like B and T lymphocytes.
Instead, they attack targets via an array of germ line encoded cell surface receptors
(5).
Like cytotoxic T lymphocytes (CTLs), NK cells mostly defend against threats by
targeting the affected cells for destruction through delivery of lytic granules (LG). This
pathway is triggered by signals from activating receptors such as NK group 2 member
D (NKG2D), which induces natural cytotoxicity (NC), or Fc receptors CD16, which
mediates antibody dependent cellular cytotoxicity (ADCC). For effective elimination of
-4-

virus-infected cells or tumor cells, NK cells have to integrate both activation receptor
signaling and inhibitory receptor signaling (3, 6). One of the most important inhibitory
signals with which NK cells must contend is that generated by PD-1.

2.1.2 PD-1
Since its discovery in 1992 by the Honjo group (7), PD-1 has emerged as a
crucial regulator of the immune system. PD-1 is expressed on the surface of a variety
of immune cells, including activated/exhausted T cells, activated/exhausted B cells,
activated monocytes, dendritic cells, regulatory T cell (T reg) (8) and NK cells (9-11).
PD-1, when bound by either of its ligands, PD-L1 (12) and PD-L2 (13), delivers
an inhibitory signal via recruitment and activation of the phosphatases SHP-1 and
SHP-2, which dephosphorylate critical signaling molecules (e.g., ZAP-70) involved in
the activation cascade downstream of activating immunoreceptors (14). Of the two,
SHP-2 appears to be the primary player, as it is the only molecule that directly interacts
with the immunoreceptor tyrosine-based switch motif (ITSM) domain of PD-1 (14). PD1 signaling can protect against tissue damage and autoimmune diseases by inducing
and maintaining T cell tolerance (11) and inhibiting self-reactive T cells (15),
respectively. However, PD-1 signaling can be maladaptive, as it is the major cause of
effector cell exhaustion during long-term, chronic antigen stimulation (11). Specifically,
PD-1 signaling blocks T, B, and NK cell functions, including proliferation (16),
development (8), cytokine (e.g., IL-2) production (17), adhesion (18), and cytotoxicity
(19).
-5-

Due to its important role in suppression of the immune response, therapeutic
approaches targeting the PD-1 pathway have garnered heavy attention from both
academic researchers and pharmaceutical companies. Of particular focus has been
antibody-mediated blockade of either PD-1 itself or its ligands, with the rationale being
that suppression of PD-1 signaling allows activation of tumor-specific CTLs or other
effector cells (e.g., NK cells) by removing the cytotoxic lymphocyte activation ‘brake’
and modifying the tumor microenvironment (20, 21). Currently, a search for ‘PD-1
blockade’ in the clinicaltrial.gov database yields 96 hits, indicating extensive clinical
research and applications focusing on blockade of PD-1 pathways.
PD-1 pathway blockade can be effective for both hematological cancer (e.g.,
leukemia) and solid cancers (e.g., myeloma, metastatic bladder cancer, and non-small
cell lung cancer) with durable clinical responses and tolerable side effects (22-24).
Additionally, PD-1 pathway blockade has the potential to restore the function of
exhausted T cells in chronic viral infection, such as HIV (25, 26), HCV (27, 28), and
HBV (29, 30). However, despite the great promise seen in these successful studies
and trials, the importance of NK cells in combating diseases, and the known effects of
PD-1 on NK cells, the precise mechanism whereby PD-1 mediates its effects in NK
cells remains poorly characterized.

2.1.3 Integrin signaling in NK cells
Integrins are heterodimeric proteins consisting of α and β subunits that bind to
the extracellular matrix and other proteins to regulate interactions among cells or matrix.
-6-

Integrins play an essential role in many processes, including cell cycle, cell adhesion
and migration (31). In mammals, there are 18 α and 8 β integrin subunits. Lymphocyte
function-associated antigen 1, also known as LFA-1, consists of a family of leukocyte
integrins that are made of αL (CD11a) and β2 (CD18) subunits. They bind to
intercellular adhesion molecule 1 (ICAM-1) expressed on other cells and function as
adhesion molecules.
The high-affinity conformation of integrins β1 and β2 families is dependent on
“inside-out” signals delivered by receptors that stimulate extension of the αβ
heterodimer and exposure of the ligand-binding site (32). In turn, the binding of integrin
to its ligand transduces “outside-in” signals, which regulate lymphocyte motility, polarity,
and adhesion. The loss of β2 integrin results in leukocyte adhesion deficiency
syndrome type I (LAD-I), which is characterized by severe abnormalities in the
adhesion-dependent functions of leukocytes (33).
No single molecule alone can be used to define ‘outside-in’ or ‘inside-out’
signaling of integrins in either NK or T cells (34, 35). In T cells, T cell receptors (TCR)
signaling alone can induce granule polarization. TCR signaling also provides strong
‘inside-out’ signals to LFA-1, and the co-engagement of LFA-1 and TCR enhances the
extent of granule polarization induced by the TCR alone (36). However, in NK cells,
the ligation of LFA-1 with ICAM-1 alone is sufficient to trigger LG polarization. Other
NK receptors are thought to be only responsible for degranulation but not LG
polarization. Thus, NK cells have proven useful in the analysis of ‘outside-in’ signaling
by LFA-1 independently of other signals (37). A recent study by Zhang et al. revealed
-7-

a signaling network centered on an integrin-linked kinase (ILK)-Pyk2-paxillin pathway
that becomes active after the binding of the integrin to its ligand (outside-in) and is
required for LG polarization in NK cells (38). ILK is recruited to immunological synapse
(IS) as shown by proximity ligation assays and its silencing impairs the polarization of
LGs in NK cells (38). In the current study, I tested whether PD-1 signaling affects this
integrin ‘outside-in’ signaling in NK cells.

2.1.4 Calcium signaling in NK cells
Uptake of extracellular calcium ions (Ca2+) is required for lymphocyte
cytotoxicity (39, 40). ORAI1 and stromal interaction molecule 1 (STIM1) were identified
as the main molecular mediators for Ca2+ entry into T cells and NK cells following the
activation of TCR and NK cell receptors, respectively. Upon receptor activation, Ca2+
is released from the endoplasmic reticulum (ER) via the activation of IP3 receptors.
STIM1, localized on the ER membrane, acts as the sensor of the ER contents and
becomes aggregated upon ER Ca2+ depletion. It then approaches the plasma
membrane and forms a physical interaction with ORAI1 to trigger extracellular Ca2+
influx. This process is termed store-operated Ca2+ entry (SOCE) (41). Significantly,
patients with mutations of ORAI1 or STIM1 have severe immunodeficiency due to
impaired SOCE (42, 43).
It has been demonstrated that SOCE via ORAI1 is critical for target cell-induced
LG exocytosis in NK cells and CTLs (39, 44). However, the involvement of Ca2+ influx
in signaling processes that mediate target cell adhesion, LFA-1 activation and LG
-8-

polarization is not clear. Although it has been shown that LG polarization is not affected
in NK cells from patients with ORAI1 mutation (44), I found a defect of LG polarization
when using BAPTA-AM to strongly block the rise in intracellular Ca2+ concentration in
NK cells. Furthermore, I also tested the effect of PD-1 engagement on Ca2+ flux in NK
cells.

In this study, I investigated the role of PD-1 in human NK cell cytotoxicity. I found
that PD-1 activation by PD-L1 blocked NK cell cytotoxicity. However, PD-1 signaling
did not inhibit cell-cell conjugation between NK and target cells, an initial step for NKmediated immune responses. Instead, NK cells that expressed PD-1 formed stable
inhibitory IS with target cells that expressed PD-L1. However, LG polarization was
blocked by PD-1 engagement via disruption of the integrin ‘outside-in’ signaling
pathway. NK cell receptor activation-induced intracellular Ca2+ concentration rise was
also abolished by PD-1 engagement. Similar to T cells, the ITSM but not ITIM domain
of PD-1 is crucial for its inhibition effect on NK cells.
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2.2 Materials and methods:
2.2.1 Cell Culture
Human Embryonic Kidney 293T (HEK293T) cells were maintained in DMEM
(Gibco, USA) with 10% fetal bovine serum (FBS, Gibco), 2 mM L-Glutamine (Gibco),
and 10 mM HEPES (Gibco). K562 and Daudi cell lines (American Type Culture
Collection, ATCC) were cultured in R10 medium, which contains RPMI 1640 medium
(Gibco) supplemented with 10% FBS, 2 mM L-Glutamine, 10 mM HEPES, 1 mM
sodium pyruvate (Cellgro, USA), and 1% MEM non-essential amino acids solution
(Gibco). CD16-KHYG-1, a human NK cell line capable of both ADCC and natural
cytotoxicity (45), was a gift from Dr. David Evans (University of Wisconsin, Madison,
WI) and cultured in R10 medium supplemented with 1 µg/ml cyclosporine A (CsA,
Sigma-Aldrich, USA), 50 µg/ml Primocin (Invivogene, USA) and 10 U/ml interleukin-2
(IL-2, Roche, USA). All cells were cultured at 37°C in a humidified atmosphere with 5%
CO2. For all experiments, the culture medium of CD16-KHYG-1 cells was replaced to
remove CsA one day before the experiments.

2.2.2 cDNA expression constructs and transduction of CD16-KHYG-1, K562, and
Daudi cell lines
The GFP, PD-1-GFP, mCherry, PD-L1-mCherry lentiviral plasmids were
generated as previously described (46). Briefly, to generate the PD-1-GFP construct,
the full length of PD-1-GFP (OriGene, USA) was subcloned into the lentiviral
expression vector, pCDH (System Biosciences, USA), using EcoRI and BamHI
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(Thermo Scientific, USA) insertion sites. To make the C-terminal mCherry-tagged PDL1 construct, the PD-L1 cDNA (OriGene) was subcloned into EcoRI and BamHI
digested pmCherry-N1 vector (Clontech, USA) first. The sequence of PD-L1-mCherry
was amplified by polymerase chain reaction (PCR) and inserted into EcoRI digested
pCDH using the In-fusion cloning system (Clontech, USA). The sequence of turboGFP
or mCherry was inserted into pCDH to create the construct for GFP or mCherry,
respectively, for lentiviral production, and for serving as experimental control.
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, USA) was
used to make PD-1 mutations on the generated PD-1-GFP lenti-plasmid. The primers
for Y223F are 5'-cagctccccaaagtccacagagaacacagg-3' and 5'-cctgtgttctctgtggactttgg
ggagctg-3', for Y248F are 5'-aatggtggcaaactccgtctgctcagggac-3' and 5'-gtccctgagcag
acggagtttgccaccatt-3'. The PD-1-GFP double mutation was made by introducing
Y223F mutation on the plasmid that already contained Y248F. All plasmids were
verified by sequencing.
To generate polyclonal stable cell lines, the lentivirus was generated by cotransfecting HEK293T cells with the desired lentiviral vector and 3 packaging plasmids
(pMLg/pRRE, pRSV-Rev, and pMD2.g) using Lipofectamine reagent (Invitrogen, USA).
Briefly, 4 µl Lipofectamine was mixed with 0.8 µg total DNA (0.128 µg desired pCDH
construct, 0.32 µg pMLg/pRRE, 0.16 µg pRSV-Rev, 0.192 µg pMD2.g) and added into
one well of HEK293T cells cultured in a 6-well plate at approximately 70% confluence.
At 48 hours after transfection, viral particles were harvested by filtering the culture
medium via a 0.45 µm filter (GE Healthcare Life Sciences, USA). Then, CD16-KHYG- 11 -

1 cells were infected with 4 ml viruses for GFP or PD-1-GFP, and K562 and Daudi cells
were infected with 4 ml viruses for mCherry or PD-L1-mCherry, at a density of 5×104
cells/ml suspended in 4 ml R10 medium. The transduced cells were cultured for 24
hours in the presence of 8.0 µg/ml polybrene (Santa Cruz Biotechnology, USA) and
subsequently sorted by an Aria II cell sorter (BD Biosciences, USA). The expression
of green or red fluorescence in these cells was verified by flow cytometry using an LSR
Fortessa cell analyzer (BD Biosciences).

2.2.3 Chromium51 release assay
NK cell cytotoxicity toward K562 or Daudi target cells was examined using a
51

Cr-release assay as described (47). Briefly, the target cells were labeled with

51

Cr at

37°C for 1 hour. After washing 3 times with fresh R10 medium, cells were resuspended in R10 medium at a density of 1105 cells/ml. An aliquot of the target cells
(0.1 ml for 1104 cells) were mixed with a serial dilution of NK cells, and the mixture
cultured at 37oC for 4 hours. At the end of the incubation, culture medium was collected
and radioactivity measured using a Topcount NXT Scintillation and Luminescence
Counter (Perkin Elmer, USA). The mean percentage of specific lysis of triplicate wells
was calculated as follows: [(test counts-spontaneous counts)/ (maximum countsspontaneous counts)] 100%.

2.2.4 Conjugation assays
NK-target conjugates were measured as described previously (48). NK cells
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and target cells (K562 or Daudi) were washed 3 times with phosphate-buffered saline
(PBS) and allowed to mix at 37°C with the densities of 1105 NK cells and 2105 target
cells per ml in total volume of 200 μl for 0 to 30 min. At the end of incubation, cells
were fixed by freshly prepared 0.5% paraformaldehyde in PBS for 15 min at room
temperature. After a gentle vortex, cells were analyzed using the LSR Fortessa flow
cytometer. The NK-target conjugates were identified as dual-color positive particles
with both green and red signals.

2.2.5 Immunofluorescence staining
An aliquot of the NK-target conjugates, as described above, was added to the
poly-lysine- coated slide, prepared as described previously (49) and allowed to settle
for 15-30 min. After the conjugates attached, the slide was washed 3 times with PBS,
and cells were fixed with 4% paraformaldehyde in PBS for 20 min. The fixed cells
were washed 3 times with PBS and permeabilized with a buffer containing 0.1% Triton
X-100 and 5% normal donkey serum before incubation with the primary antibodies at
4°C overnight. The primary antibodies were: perforin (G9, Pierce Chemical Co.) and
ILK (Abcam). The cells were washed and probed with the fluorophore-conjugated
secondary antibodies (Invitrogen, USA) at room temperature for 1.5 hours. When
needed, Alexa Fluor dye-conjugated phalloidin (Invitrogen, USA) was used to stain Factin. The slide was mounted with a glass coverslip using the ProLong Gold antifade
reagent containing DAPI (Life Technologies, USA).
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2.2.6 Laser scanning fluorescence confocal microscopy
For live cell imaging, high-resolution images were captured by a confocal
fluorescent microscope (Leica TCS SP8, Leica Microsystem, Germany) equipped with
a 63× oil immersion objective lens (NA 1.47, Leica Microsystem) under 37°C. The
fluorescence from GFP, mCherry, and the bright field images were detected
simultaneously. For imaging fixed cells, images were acquired using the LASAF
software (Leica Microsystem). Three-dimensional (3D) images were reconstructed
from acquired z-stacks of X-Y scanning of entire cells for perforin, F-actin, and ILK.
ImageJ was used for image processing and creating projected images from 3D
reconstructions.
To measure the distance between LGs (perforin staining) and IS (F-actin
staining), ImageJ and Imaris (Bitplane) software were used. From the 3D image,
coordinates for the center of a “dot” (perforin, x1, y1, z1) and that of the “surface”
(accumulated F-actin, x2, y2, z2) were obtained for each conjugate, and entered into
the equation:

=

(x1 − x2) + (y1 − y2) + (z1 − z2) , where D is the average

distance of every perforin to the center of the IS for each pair of NK-target conjugate.

2.2.7 Intracellular Ca2+ measurement
A ratiometric dye, Indo1-AM (ThermoFisher Scientific, USA), was used for
measuring intracellular Ca2+ concentrations. For each condition, 5105 NK cells were
incubated with 1 μM Indo1-AM in R10 medium for 30 min in the cell culture incubator.
The cells were then washed with PBS once and incubated with primary antibodies on
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ice for 30 min in 200 μl extracellular solution (ECS) that contains 140 mM NaCl, 2 mM
CaCl2, 5 mM KCl, 1 mM MgCl2, 10 mM Glucose, 10 mM HEPES, pH 7.4. The primary
antibodies were: anti-CD16, anti-NKG2D and anti-PD-1 (Biolegend, USA). The
antibody-coated cells were then washed once with cold PBS, resuspended in 500 μl
ECS, and then subject to fluorescence-activated cell sorting (FACS). An ultraviolet (UV)
laser (355 nm) was used to excite Indo1, and two filters (DAPI 405/20, Indo1 525/50)
were used to collect the emission signals. Before each experiment, cells were warmed
in a 37°C water bath for 5 min. To trigger the Ca2+ response, a secondary goat F(ab)2
anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, Inc., USA) was
added to each sample and mixed by vortex. To distinguish ER Ca2+ release from
extracellular Ca2+ influx, ECS without added Ca2+ was used first and ECS containing 4
mM CaCl2 was introduced after ER Ca2+ mobilization had subsided. For some
experiments, BAPTA-AM (ThermoFisher Scientific, USA) was used to chelate the
intracellular Ca2+ and thus abolish the Ca2+ response. Thapsigargin (TG) (Sigma, USA),
phorbol 12-myristate 13-acetate (PMA) (Sigma, USA), and ionomycin (Sigma, USA)
were used to trigger Ca2+ responses as needed. The data were analyzed by FlowJo
software. Calcium signal was indicated by the ratio of the fluorescence intensities
acquired at 405 and 525 nm emission wavelengths.

2.2.8 Statistical analysis
Unpaired or paired two-tailed t-tests were performed using Prism software (GraphPad
Software, Inc.).
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2.3 Results
2.3.1 PD-1 signaling attenuates NK cell cytotoxicity
As a first step to understand PD-1 signaling in NK cells, I generated a stable
CD16-KHYG-1 cell line expressing PD-1-GFP (NK-PD-1-GFP). CD16-KHYG-1 is a
human NK cell line that recognizes and kills target cells, such as K562 and Daudi cell
lines, through two distinct mechanisms: natural cytotoxicity (NC) through activating
receptors, such as NKG2D (50), and antibody-dependent cellular cytotoxicity (ADCC)
through CD16 (3),(51). To test NC and ADCC of NK cells in response to PD-1 signaling
blockade, K562 and Daudi cell lines stably expressing the PD-1 ligand, PD-L1mCherry (named as K562-PD-L1-mCherry and Daudi-PD-L1-mCherry, respectively),
were used as target cells. CD16-KHYG-1 and K562 (or Daudi) cell lines stably
expressing GFP only or mCherry only (named as NK-GFP, K562-mCherry, and DaudimCherry) were used as respective controls. The expression of GFP in the stable
CD16-KHYG-1 cell lines and that of mCherry in the stable K562 and Daudi cell lines
were verified by flow cytometry (Figure 4, left panels). Using PD-1 and PD-L1
antibodies, I showed that more than 95% cells expressed PD-1 and PD-L1 in the NKPD-1-GFP and K562-PD-L1-mCherry (or Daudi-PD-L1-mCherry) cells, respectively.
However, no PD-1 staining was seen in the parental wild-type CD16-KHYG-1 cells or
NK-GFP cells, and no PD-L1 was detected in the wild-type or mCherry-expressing
K562 or Daudi cells (Figure 4, right panels). Thus, I successfully established a PD1-positive NK cell line and PD-L1-positive target cells and their control groups for
testing the effects of PD-1 signaling on NK cell cytotoxicity.
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Figure 4. Verification of PD-1 and PD-L1 protein expression in NK and target cells,
respectively, by flow cytometry. First row, histograms of wild-type (gray), and GFP- (green),
or PD-1-GFP- (red) transduced CD16-KHYG-1 cells tested by flow cytometry for GFP
fluorescence (left) and APC-tagged PD-1 antibody staining (right). Second and third rows,
histograms of wild type (gray), and mCherry- (blue) or PD-L1-mCherry- (red) transduced K562
(second row) and Daudi (third row) cells measured by flow cytometry for mCherry florescence
(left) and FITC-tagged PD-L1 antibody staining (right).
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First, I examined the subcellular distribution of the expressed PD-1-GFP and
PD-L1-mCherry in transduced cells. Prominent plasma membrane localization and
intracellular aggregation of PD-1 and PD-L1 was observed in cells expressing PD-1GFP and PD-L1-mCherry (Figure 5, left panels), but not in cells expressing GFP only
and mCherry only (Figure 5, right panels). Plasma membrane localization and
intracellular aggregation have previously been reported for endogenous PD-1 in
primary T cells (52). Therefore, the subcellular localization of the expressed PD-1 and
PD-L1 in the stable CD16-KHYG-1 and K562 (and Daudi) cells resembled that of
endogenous PD-1 in primary T cells.

Figure 5. Fluorescence protein-tagged PD-1 and PD-L1 are expressed on the plasma
membrane of NK and target cells, respectively. Representative confocal DIC and
fluorescence images of GFP and mCherry for single cells that expressed GFP or PD-1-GFP
(green) in CD16-KHYG-1 and mCherry or PD-L1-mCherry (red) in K562 or Daudi cells. Scale
bars: 5 μm.
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To test the effect of PD-1 signaling on the cytotoxicity of NK cells, I examined
the NC and ADCC ability of NK-PD-1-GFP cells using a chromium-51 (51Cr) release
assay. For NC, NK-GFP and NK-PD-1-GFP cells were co-incubated for 4 hours with
51

Cr-loaded K562-mCherry or K562-PD-L1-mCherry cells, whereupon the amount of

51

Cr in the medium was determined. The results showed that co-incubation of NK-PD-

1-GFP cells with K562-PD-L1-mCherry cells inhibited the cytotoxicity of NK cells
against K562 (Figure 6B), but NC was unaffected without engagement of PD-1 and
PD-L1 (Figure 6A, B). Similarly, ADCC, as examined using Daudi-mCherry or DaudiPD-L1-mCherry cells as NK target cells, induced by rituximab (anti-CD20) (preincubated with Daudi cells for 30-60 min before mixing with the NK cells) was abolished
only when NK-PD-1-GFP cells were co-incubated with Daudi-PD-L1-mCherry cells
(Figure 6D). Co-incubation of CD16-KHYG-1 cells expressing PD-1 with Daudi cells
not expressing PD-L1 or co-incubation of Daudi cells expressing PD-L1 with CD16KHYG-1 cells not expressing PD-1 did not alter ADCC (Figure 6C, D). The NK cells
failed to trigger ADCC towards Daudi cells without rituximab (Figure 7). Thus, the
engagement of PD-1 with its natural ligand is required for inhibition of NC and ADCC.
PD-1 signaling attenuates NK cell cytotoxicity.
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Figure 6. PD-L1-positive target cells inhibit the cytotoxicity of PD-1-positive NK cells. The
natural cytotoxicity (NC) of CD16-KHYG-1 cells expressing GFP (NK-GFP) (A) or PD-1-GFP
(NK-PD-1-GFP) (B) towards K562 cells that expressed either mCherry (K562-mCherry) or
PD-L1-mCherry (K562-PD-L1-mCherry) was measured by a standard 4-hour

51

Cr-release

assay with varying NK/K562 (effector/target) ratios. The antibody-dependent cellular
cytotoxicity (ADCC) of NK-GFP (C) or NK-PD-1-GFP (D) towards Daudi cells that expressed
mCherry (Daudi-mCherry) or PD-L1-mCherry (Daudi-PD-L1-mCherry) was measured by the
51

Cr-release assay in the presence of rituximab, which was pre-incubated with Daudi cells for

30 min and present throughout the 4-hour incubation period. Results are representatives of three
independent experiments. Error bars represent SDs. NS, Not significant. *, p＜0.05.
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Figure 7. NK cells cannot perform ADCC without rituximab. The ADCC of NK-GFP and
NK-PD-1-GFP towards Daudi-mCherry or Daudi-PD-L1-mCherry was measured by the 51Crrelease assay in the absence of rituximab with varying NK/Daudi (effector/target) ratios.

2.3.2 Stable immunological synapse formation in NK cells in the presence of PD1 signaling
The unaltered killing capability of NK-PD-1-GFP cells on PD-L1-negative target
cells indicated that the activating receptors functioned normally in the transduced
CD16-KHYG-1 cells in the absence of PD-L1. Indeed, by antibody staining, I showed
that neither GFP nor PD-1-GFP affected the surface expression of CD16 or NKG2D
(Figure 8), the major activating receptors in CD16-KHYG-1 cells that mediate NC and
ADCC, respectively, indicating that PD-1 overexpression or lentivirus infection did not
change the expression of these two major activating receptors in NK cells. Therefore,
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it was likely that the PD-1/PD-L1 ligation directly inhibited the cytotoxicity of NK cells
through interference with the function of its activating receptors.
To further understand the underlying molecular basis of PD-1 inhibition of
human NK cytotoxicity, I investigated the role of PD-1 in regulating formation of the NK
IS, a pivotal platform for mediating an effective immune response in both the adaptive
and innate immune systems (46, 53, 54). For cytotoxic killing, an IS forms between the
lymphocyte and the target cell, where activating receptors accumulate followed by
release of LGs (55). To determine whether PD-1 in NK cells binds to IS with PD-L1
from their susceptible target cells, NK-GFP and NK-PD-1-GFP cells were allowed to
form conjugates with K562 or Daudi cells that expressed either mCherry only or PDL1-mCherry in a 1:1 ratio, and were then inspected by confocal microscopy. As shown
in Figure 9 & 10, PD-1-GFP accumulated in IS only when the NK-PD-1-GFP cells were
conjugated with K562 (for examining NC) or CD20 antibody pretreated Daudi cells (for
examining ADCC) that expressed PD-L1-mCherry, which was also concentrated at the
IS. The accumulation occurred within minutes and persisted for more than four hours,
resembling that reported for T cells (52, 56) and inhibitory IS formation in NK cells (46).
By contrast, if the target cells expressed mCherry only instead of PD-L1-mCherry, PD1-GFP did not accumulate at the IS. Vice versa, PD-L1-mCherry failed to concentrate
at the IS without the expression of PD-1-GFP in the NK cells (Figure 9 & 10). We
conclude that stable inhibitory IS is formed in NK cells only in the presence of PD-1
signaling in both NC and ADCC.
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Figure 8. GFP or PD-1-GFP expression does not affect the surface expression of activating
receptors CD16 and NKG2D in NK cells. Histograms of flow cytometry analyses of cell
surface staining by CD16 (left) and NKG2D (right) antibodies in wild-type (black), and GFP(green) or PD-1-GFP- (red) transduced CD16-KHYG-1 cells.
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Figure 9. PD-1 and PD-L1 molecules accumulate at immunological synapse (IS) in NK
cells. Live-cell imaging of NK-GFP or NK-PD-1-GFP effector cells (green) conjugated with
target cells (red) that expressed mCherry or PD-L1-mCherry. K562 cells were used as CD16KHYG-1 susceptible target cells for evaluating NC. The effector/target pairs were mixed at a
1:1 ratio. Representative live cell images were taken by confocal microscopy at 15-60 min after
conjugation. Scale bars: 5 μm. IS was identified by the colocalized green and red signals (yellow
in the merged images at right) in the bottom panels. Fluorescence intensity profiles of green
and red signals as indicated were measured across the white line in the right panel.
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Figure 10. PD-1 and PD-L1 molecules accumulate at immunological synapse (IS) in NK
cells. Live-cell imaging of NK-GFP or NK-PD-1-GFP effector cells (green) conjugated with
target cells (red) that expressed mCherry or PD-L1-mCherry. Daudi cells in the presence of
rituximab were used as CD16-KHYG-1 susceptible target cells for evaluating ADCC. The
effector/target pairs were mixed at a 1:1 ratio. Representative live cell images were taken by
confocal microscopy at 15-60 min after conjugation. Scale bars: 5 μm. IS was identified by the
colocalized green and red signals (yellow in the merged images at right) in the bottom panels.
Fluorescence intensity profiles of green and red signals as indicated were measured across the
white line in the right panel.
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2.3.3 PD-1 signaling does not affect NK-target cell conjugation
NK cytotoxicity involves multiple distinct steps, including conjugation with target
cells, LG polarization, degranulation and cytotoxicity (53). The engagement of PD-1
with PD-L1 inhibited cytotoxic killing of target cells by CD16–KHYG-1, suggesting the
formation of inhibitory synapses between PD-1 expressed in the NK cells and PD-L1
expressed in the target cells. My live imaging data shown above indeed demonstrated
the close apposition between PD-1-GFP and PD-L1-mCherry expressed in NK and
target cells, respectively, at the IS, which remained stable for hours (Figure 9 & 10).
However, whether this represented stable conjugations between NK cells and target
cells and how it compared to cells that did not express the inhibitory receptor were
unclear.
To address this question, I used flow cytometry to determine the percentage of
CD16-KHYG-1 cells that were conjugated with target cells. Interestingly, no difference
in the percentage of GFP and mCherry double-positive conjugates was observed over
the period of 30 min in either the NC (Figure 11A) or the ADCC (Figure 11B) assays
among the different combinations of NK and target cells, with or without PD-1 and PDL1 expression. Together, these results indicate that the PD-1/PD-L1 engagement does
not affect the conjugation of NK cells with their target cells, which indicates that the
PD-1 signaling may affect the downstream steps of NK cytotoxicity.
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Figure 11. PD-1 signaling does not affect the conjugation between NK and target cells.
NK-GFP or NK-PD-1-GFP cells were mixed with their target cells, as indicated, at a 1:2 ratio
for 30 min. Cells were fixed, and then analyzed by flow cytometry. The ratios of GFP and
mCherry double-positive events to total GFP-positive NK cells were calculated to determine
the percentage of conjugation. K562 cells (A) were used for NC and Daudi cells (B) were used
for ADCC, where rituximab was included throughout the experiment. Error bars represent SDs.
Data are from three independent experiments. NS, Not significant.
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2.3.4 PD-1/PD-L1 engagement blocks lytic granule polarization at immunological
synapse of the NK cell
After conjugation with target cells, LGs in NK cells, which contain perforin,
become polarized to the IS (49, 55). This represents another key step of cytotoxic
killing (57). To examine if PD-1/PD-L1 engagement affected LG polarization in NK cells,
I measured the distance of perforin-labeled LGs to the IS in target-conjugated CD16–
KHYG-1 cells that expressed GFP or PD-1-GFP. Cells were co-stained for F-actin and
perforin, and 3D fluorescence images of individual cell conjugates were collected by
confocal microscopy. In these images, NK cells were identified by positive staining with
perforin; the IS was indicated by the accumulated F-actin signal at the boundary
between NK and the target cells (55). The distance between perforin, modeled as a
“round dot” and the accumulated F-actin, modeled as the “surface”, was determined
using Imaris software (Bitplane) and plotted for individual NK cells (Figure 12).
In both the NC and ADCC models, the distance between the perforin positive
LGs and the IS was significantly increased in conjugates formed between NK-PD-1GFP cells and the target cells that expressed PD-L1-mCherry, as compared to that
between NK-GFP cells and targets that expressed mCherry only at 30 min after
conjugation (Figure 12). The LG also failed to polarize on IS at later time points (60
min ,120 min) in the presence of PD-1 signaling (Figure 13), exclude the possibility
that granule polarization could still occur during PD-1 engagement with different
kinetics. PD-1/PD-L1 engagement rendered the LGs of the NK cells unable to reach
the IS for successful killing of their susceptible target cells. Thus, PD-1/PD-L1
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engagement specifically blocks LG polarization at inhibitory NK IS.

Figure 12. PD-1 engagement blocks lytic granule (LG) polarization. Conjugates were made
between NK and target cells as indicated. Cells were fixed and stained with anti-perforin (green,
for LGs), phalloidin (red, for F-actin staining), and DAPI (blue, for nuclei staining).
Representative images for 3D-reconstruction projections of paired cells are shown for NC (A)
and ADCC (B). NK cells were identified by perforin staining. IS was identified by accumulated
F-actin. Scale bars: 5 μm. The mean distance of the perforin cluster to IS in each NK-target
conjugate (represented by individual data points) was calculated using Imaris software and
summarized in the right panel. The average values and SDs are shown by the horizontal lines
(****, p ≤0.0001, by Student’s t test).
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Figure 13. PD-1 engagement constantly blocks lytic granule polarization. The mean
distance of the perforin cluster to IS in each NK-target conjugate (represented by individual
data points) was calculated and summarized for each indicated time point after conjugation.
“G+m” represents NK-GFP conjugated with K562-mCherry; “P+L” represents NK-PD-1-GFP
conjugated with K562-PD-L1-mCherry. The average values and SDs are shown by the
horizontal lines (NS, Not significant; ****, p ≤ 0.0001, by Student’s t test).
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2.3.5 PD-1 signaling inhibits integrin signaling
The integrin signaling pathway regulates LG polarization in NK cells (38). In
response to either antibody stimulation of the activating receptors or the activation of
leukocyte function–associated antigen 1 (LFA-1, also called αLβ2 integrin) by its ligand,
intercellular adhesion molecule 1 (ICAM-1), the LGs along with the microtubuleorganizing center (MTOC) in the NK cell, polarize towards the target cell. This process
requires a signaling network consisting of integrin-linked kinase (ILK), Pyk2, paxillin,
and several other proteins, among which ILK also accumulates at the IS in response
to NK cell activation (38). To gain insights into the functional relationship between PD1/PD-L1 engagement and integrin-mediated adhesion and consequent LG polarization,
I co-stained ILK and perforin in target-conjugated NK-GFP and NK-PD-1-GFP cells.
Confocal fluorescence imaging revealed that while both ILK and perforin concentrated
in the IS between the majority of conjugated NK-GFP and K562-mCherry cells at 30
min and 60 min after conjugation (Figure 14B), indicative of accumulation at the IS.
Although the accumulation dropped at 120 min in control groups, ILK appeared as
dispersedly distributed puncta in most of the conjugated NK-PD-1-GFP and K562-PDL1-mCherry cells at all the time points we tested (Figure 14). Similar to that shown in
Figure 12, perforin positive LGs also did not move to the IS between the two cells. To
rule out the possibility of decreased overall expression of integrin molecules in NK cells
transduced with PD-1, I measured the mean fluorescence intensity (MFI) of LFA-1
using flow cytometry and found comparable overall expression of LFA-1 in NK cells
transduced with either GFP only or PD-1-GFP (Figure 15). Therefore, we concluded
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that PD-1/PD-L1 engagement disrupted integrin signaling, known to be required for LG
polarization in NK cells.

Figure 14. PD-1 signaling blocks the accumulation of ILK to IS in NK cells. Conjugates
were made between NK and K562 cells as indicated. Cells were fixed and stained with antiperforin (green), anti-ILK (red), and DAPI (blue, for nuclei). (A) Representative images of 3Dreconstruction projections of paired NK-K562 cells without (upper panels) and with (lower
panels) PD-1/PD-L1 engagement at 30 min after conjugation. Scale bars: 5 μm. (B)
Quantification of the percentage of NK-target conjugates showing accumulation of ILK at IS
at different time points after conjugation. N indicates the total number of conjugates counted.
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Figure 15. PD-1-GFP expression does not affect the overall expression of LFA-1 in NK
cells. Histogram of flow cytometry analysis of the staining by LFA-1 antibody in GFP- (green)
or PD-1-GFP- (red) transduced CD16-KHYG-1 cells.
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2.3.6 PD-1 signaling blocks receptor-activated calcium response in NK cells
The increase of intracellular Ca2+ level is also an important indicator for the
activation of NK cells. It has been showed that activating receptor induced storeoperated Ca2+ entry (SOCE) through ORAI channels is required for the cytotoxicity of
NK cells. Calcium is also important for the exocytosis of cytotoxic granules to release
perforin and Granzyme B (44). To test whether calcium is also crucial for LG
polarization, I loaded NK cells with the chelator BAPTA to suppress intracellular Ca2+
rise. Not only the Ca2+ response triggered by PMA/ionomycin was largely abolished in
the BAPTA-loaded NK cells (Figure 16A), but also LG failed to polarize to the IS
(Figure 16B).
To investigate the effect of PD-1 on the activation of NK cells, I examined the
Ca2+ response to different activating receptors in the presence of PD-1 signaling. Since
NKG2D is mainly responsible for NC, and CD16 is to mediate ADCC, I first measured
the effect of PD-1 signaling on Ca2+ response induced by these activating receptors in
normal ECS that contains 2 mM CaCl2. Cross-linking CD16 or NKG2D through primary
and secondary antibodies evoked intracellular Ca2+ concentration increase in CDKHYG1-1 cells that expressed either GFP or PD-1-GFP (Figure 17). Cross-linking
using the PD-1 antibody alone did not trigger any Ca2+ response. When I activated
activating receptor and PD-1 together, the Ca2+ response was totally abolished in the
NK-PD-1-GFP cells but unaffected in NK-GFP cells (Figure 17). These results suggest
that activation of PD-1 specifically inhibit the Ca2+ response elicited by NK cell
activating receptors
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The receptor-induced Ca2+ response has two distinct phases. In the first phase,
Ca2+ is released from the ER via IP3 receptors (IP3R). In the second phase or SOCE,
the decrease in ER Ca2+ content signals influx of extracellular Ca2+ via plasma
membrane Ca2+ channels such as ORAI (41). To investigate whether PD-1 signaling
preferentially affects ER Ca2+ store depletion or Ca2+ influx, cells were placed in a Ca2+free ECS first and then Ca2+ (2 mM) was added back. Under these conditions, the
activation of CD16 alone triggered a transient intracellular Ca2+ response in the Ca2+free ECS (Figure 18) representing ER Ca2+ release. This response was abolished by
cross-linking the cells with the PD-1 antibody, which did not elicit a response on its
own. Therefore, the activation of PD-1 signaling blocked the ability of activating
receptors to cause ER Ca2+ release.
Upon increasing the extracellular Ca2+ concentration to 2 mM, the intracellular
Ca2+ level also went up, indicative of extracellular Ca2+ influx (Figure 18). Here, a large
background “Ca2+ leak” appeared in these cells as seen by the robust increase in the
Indo1 ratio in cells treated with the anti-PD-1 antibody. SOCE was shown by the extra
peak in the CD16 antibody-treated cells on top of the “Ca2+ leak” (Figure 18).
Importantly, in the presence of PD-1 activation, the CD16 antibody no longer evoked
SOCE (Figure 18), suggesting that the activating receptor-induced SOCE is also
blocked by PD-1 signaling. This is expected since SOCE is activated as a
consequence of ER Ca2+ store depletion. As a control, I used thapsigargin (TG) to
deplete the ER Ca2+ and examined SOCE using the above Ca2+-free/Ca2+ readdition
protocol. In this case, the engagement of PD-1 failed to block TG-induced ER Ca 2+
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release and SOCE (Figure 19), suggesting that the inhibitory action of PD-1 signaling
is at the level downstream from activating receptor activation but before ER Ca2+
release.
I noticed that in some of the PD-1/PD-L1 conjugates, perforin could still reach
the IS (Figure 12&13). Therefore, the ability of PD-1 signaling to abolish the Ca2+
response

induced

by

the

activating

receptors

may

further

inhibit

the

exocytosis/degranulation of the LGs. Taken together, my data indicate that PD-1
signaling may use redundant mechanisms, inhibiting granule polarization and Ca2+
response, to block the activation of NK cells. This may help ensure the silence of
immune response. However, it cannot be ruled out at this point that the Ca2+ signal is
also involved in granule polarization to the IS, as a part of the ‘outside-in’ integrin
signaling.
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Figure 16. BAPTA blocks LG polarization. NK cells loaded with Indo1-AM dye were treated
with PMA/ionomycin (P/I) while fluorescence ratios of Indo1 were recorded by flow cytometry.
A. Representative time course of Indo1 ratios in control (red) NK cells and cells pre-incubated
with BAPTA-AM for 30 min (blue). B. NK cells pre-loaded with BAPTA-AM for 30 min were
conjugated to wild type K562 cells, fixed and stained with anti-perforin (magenta, for LGs),
phalloidin (cyan, for F-actin staining), and DAPI (blue, for nuclei staining). Representative
images for 3D-reconstruction projections of paired cells are shown. Scale bars: 5 μm.
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Figure 17. PD-1 signaling blocks Ca2+response in NK cells. A. NK-GFP (left) and NK-PD1-GFP (right) cells were loaded with Indo1-AM dye. Intracellular calcium rise (shown by the
increase of Indo1 ratio) was triggered by crosslinking the cells with anti-NKG2D and the
secondary antibodies. Representative time courses of Indo1 ratio changes are shown for cells
crosslinked by antibodies for NKG2D alone (blue), PD-1 alone (black), or NKG2D+PD-1 (red).
B. Summary of normalized peak values for treatments as indicated. C. Summary of normalized
peak values for cells treated with CD16 and PD-1 antibodies as shown in similar fashions as
(A). Error bars represent SDs. Data are from three independent experiments. NS, Not
significant. ****, p ≤ 0.0001, by Student’s t test.
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Figure 18. PD-1 signaling blocks both ER calcium release and receptor activationdependent Ca2+ influx in NK cells. NK-PD-1-GFP cells loaded with Indo1-AM dye were
coated with antibodies for CD16 alone (red), PD-1 alone (green), or CD16+PD-1 (blue) in a
Ca2+-free ECS and Indo1 fluorescence ratios were recorded 30 seconds to establish the
baselines. The cells were then treated with F(ab)2 secondary antibody to induce crosslinking in
the Ca2+-free ECS, followed by the addition of an equal volume of ECS containing 4 mM CaCl 2
(final extracellular Ca2+ concentration of 2 mM) as indicated. Shown are representative time
courses of three independent experiments.
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Figure 19. PD-1 signaling does not block pharmacological store-operated calcium entry.
NK-PD-1-GFP cells loaded with Indo1-AM dye were coated (red) or not (cyan) with the
antibody for PD-1 in the Ca2+-free ECS and recorded for 30 seconds to establish the baselines.
The cells were then treated with F(ab)2 secondary antibody for crosslinking before the application
of TG (2 μM) to cause passive ER Ca2+ store depletion in the Ca2+-free ECS, independent of
activating receptors. Finally, 2 mM CaCl2 was added back to ECS by mixing the equal volume
of ECS that contained 4 mM CaCl2.
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2.3.7 ITSM domain is required for the inhibitory function of PD-1
Previous data showed that the ITSM instead of ITIM domain of PD-1 is crucial
for its function in T cells (14). To investigate whether this is also the case in NK cells, I
tested the involvement of these two domains in PD-1 inhibition of NK cell cytotoxicity.
I made the Y223F mutation at ITIM or the Y248F mutation at ITSM to disrupt the
functions of each domain, as well as the dboule Y223F/Y248F mutant to interrupt both
domains. NK cells that expressed single mutations as well as that with double mutation
were established by lentivirus transduction as described above for the wild type PD-1.
First, I showed that none of the mutations affected the conjugation of NK and target
cells and the mutated PD-1-GFP proteins were still able to accumulate at the IS with
PD-L1 (Figure 20). Then, I used the

51

Cr release assay to test the cytotoxicity of the

NK cells that expressed different PD-1 mutations. In both NC and ADCC, the Y248F
mutant and double mutant failed to exhibit inhibition of NK cell cytotoxicity to PD-L1
expressing cancer cells, whereas the Y223F mutant exerted a similar level of inhibition
as the wild type PD-1 (Figure 21). These data indicate that similarly as it does in T
cells, the ITSM domain (containing Y248) of PD-1 is also important for its inhibitory
action in NK cells for both NC and ADCC. The ITIM domain (containing Y223) of PD1, however, is not involved in the inhibition effect of PD-1 in NK cells.
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Figure 20. PD-1 mutants accumulate at IS normally with PD-L1. Live-cell imaging of NK
effector cells (green) that stably expressed mutant PD-1-GFP as indicated (cyan) and
conjugated with target K562-PD-L1-mCherry cells (red). Images were taken by confocal
microscopy at 30 min after conjugation. Scale bars: 5 μm. IS is shown as the co-localized green
and red signals (yellow).
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Figure 21. Y248 of PD-1 is crucial for its inhibition of NK cell cytotoxicity. (A) The natural
cytotoxicity (NC) of CD16-KHYG-1 cells stably expressing PD-1-GFP (black), or PD-1-GFP
mutations Y223F (green), Y248F (red), and Y223,248F (blue) towards K562-PD-L1-mCherry
was measured by the standard 4-hour 51Cr release assay at varying NK/K562 (effector/target)
ratios. (B) The ADCC of the same set of NK cells towards Daudi-PD-L1-mCherry was
measured by the 51Cr-release assay in the presence of rituximab. Results are representatives of
three independent experiments. Error bars represent SDs.
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2.4 Summary, discussion and future directions
In this study, I show that PD-1 signaling blocks NK cell-mediated immune
responses through impairing LG polarization to the NK cell IS. Neither NK-target cell
conjugation nor NK-target cell IS formation was blocked by PD-1 engagement. In NK
cells, PD-1 functions as an inhibitory receptor through its ITSM domain, similar that in
cytotoxic T cells and other lymphocytes (28, 58). The engagement of PD-1 expressed
in NK cells with its ligand PD-L1 expressed on NK-sensitive target cells inhibited both
forms of NK-mediated cytotoxicity, NC and ADCC. The engagement of PD-1 blocked
ILK-mediated integrin ‘outside-in’ signaling, which may account for the interference of
LG polarization and the consequent inhibition of cytotoxicity. Furthermore, PD-1
signaling blocks activating receptor-induced Ca2+ response in NK cells, which may also
account for the inhibition of LG polarization and degranulation (Figure 22).
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Figure 22. Schematic working model. In the absence of PD-1/PD-L1 engagement (left), when
the NK cell encounters a target cell, the activation of activating receptors in the NK cell induces
the accumulation of ILK and perforin-containing granules to the IS, which is accompanied with
elevated intracellular Ca2+ concentration. This leads to a consequent degranulation and
cytotoxic killing of the target cell. However, in the presence of PD-1/PD-L1 engagement (right),
which evokes inhibitory signaling, the polarization of perforin and ILK is blocked and the Ca2+
response is abolished, resulting in the inhibition of NK cytotoxicity and survival of the target
cell.

2.4.1 PD-1 and IS stability
It remains controversial whether inhibitory receptors alter IS stability. Some
previous studies have suggested that inhibitory receptors destabilize the NK IS,
causing the NK cell to disengage from its target before it can successfully initiate a
cytolytic attack (59, 60). This concept also gained support from experiments with
mouse CD4+ T cells, where continued PD-1/PD-L1 interactions destabilized adhesion
of self-reactive CD4+ T cells in the pancreas by inhibiting the TCR-driven ‘stop signals’,
blockade of PD-1 or PD-L1 prolonged T cell-dendritic cell (DC) engagement (18), and
PD-1/PD-L1 binding blocked stable synapse formation on supported glass-supported
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lipid bilayers containing PD-L1 molecules (56). However, this observation is in contrast
to that found for long-term (> 40 min) PD-1/PD-L1 interactions in virus-specific CD8 + T
cells in mice chronically infected with lymphocytic choriomeningitis virus (LCMV) clone
13 (a strain establishes persistent viral infection) (61). Nevertheless, in the current
study, we demonstrated that NK cells can form stable IS even when the inhibitory
signaling dominates as reported before (49, 62). The discrepancy may be explained
by the differential impact of PD-1 signaling on cytotoxic lymphocytes (including NK and
CD8+ T cells) and CD4+ T cells due to different downstream signaling cascades.
Moreover, it has been reported that inhibitory receptor signaling does not block
accumulation of activating receptors (49, 62). This has been shown with 2B4 and CD2
both accumulated at inhibitory synapses with target cells (62) and with the minimal
combination of activation ligand human IgG1 Fc (a ligand for the low affinity Fc receptor
FcRIIIA, also known as CD16) and HLA-E (a ligand for inhibitory receptor
CD94/NKG2A) (49). Recently, using a newly developed vertical cell pairing (VCP)
system, my colleagues and I showed the formation of a stable inhibitory IS after
engaging PD-1 expressed on NK cells with PD-L1 expressing target cells (46),
supporting the idea that stable inhibitory IS formation indeed occurs during inhibitory
signaling in NK cells. These results await further validation with a large sample size,
but meanwhile bring a question whether inhibitory receptor signaling acts through
destabilization of the IS in NK cells or through other unidentified molecular
mechanisms. My data strongly support the notion that PD-1 inhibits NK cells through
disruption of downstream intracellular signaling following IS formation rather than
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disruption of IS formation per se. However, further studies should be done to check
whether PD-1 signaling affect the accumulation of activating receptors and the
activating synapse.

2.4.2 PD-1 and integrin ‘outside-in’ signaling induced LG polarization in NK cells
The current study shows that PD-1 signaling does not decrease the percentage
of NK-target cell conjugation. Usually, cell-cell adhesion is the initial step in immune
responses (53, 63, 64). After effector-target conjugation, immunoreceptors on the NK
cell surface then bind to their respective ligands on the target cell surface and initiate
immune signaling, which can be either activating or inhibitory, depending on which
receptors are engaged. The current dogma is that inhibition of early signaling (e.g.,
adhesion) is more effective at suppressing NK cell activation than blocking the later
phases of signaling. Unexpectedly, however, my data show that PD-1 inhibitory
signaling preferentially blocks integrin-mediated LG polarization without affecting NKtarget cell adhesion or cell-cell conjugation. Based on the crystal structure, the
extracellular region of PD-1 is a short single immunoglobulin variable (IgV) domain
(65). Integrins are much longer, so it makes sense that PD-1 could only be engaged
after some integrin signaling had already occurred.
It is well appreciated that, for cytotoxic killing, integrin molecules in CTL possess
both ‘inside-out’ signaling and ‘outside-in’ signaling (32, 66). LFA-1-dependent
‘outside-in’ signaling in T cells requires ‘inside-out’ signaling to enhance polarization of
LGs (36), but it is not known whether LFA-1 receives TCR-dependent ‘inside-out’
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signals merely to promote adhesion or to provide essential signals for polarization. In
contrast, NK cells have proven useful in the analysis of ‘outside-in’ signaling by LFA-1
independently of other signals because the binding of LFA-1 on NK cells to ICAM-1 on
target cells is sufficient to induce the polarization of LGs to NK IS (37). Therefore,
‘outside-in’ and ‘inside-out’ signaling can be generally measured by LG polarization
and conjugate formation assays, respectively, in NK cells. My data suggest that PD-1
preferentially impairs LFA-1-dependent ‘outside-in’ signaling, rather than ‘inside-out’
signaling pathway. This differs from the recent studies in T cells, in which the
engagement of PD-1 with its physiological ligand inhibited T cell adhesion (67, 68).
The different LFA-1 signaling pathways between T and NK cells could cause this
discrepancy (69).
The fact that PD-1 engagement preferentially blocks LG polarization to the NK
cell IS is reminiscent of previous studies showing that inhibitory receptors block signals
for LG polarization (by integrin LFA-1) more effectively than signals for degranulation
(69). Using a Drosophila cell line S2 transfected with various ligands of human NK cell
receptors, Das and Long investigated whether inhibitory receptors could block LG
polarization and degranulation. They showed that LG polarization was highly sensitive
to inhibition mediated by killer cell immunoglobulin-like receptor (KIR) and CD94NKG2A receptors (69). However, this study did not specifically define the underlying
molecular basis of this inhibition. In the current study, I discovered that PD-1 signaling
specifically blocked polarization of the common integrin signaling molecule ILK at the
NK cell IS. To our knowledge, although PD-1 signaling is well characterized in T cells
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and SHP-2 is the only cellular molecule that directly interacts with immunoreceptor
tyrosine-based switch motif (ITSM) domain of PD-1 (11), ILK is a newly-identified
molecule targeted by PD-1 signaling. The underlying mechanisms of how PD-1
signaling blocks ILK polarization at the NK cell IS requires further investigation.

2.4.3 Calcium and LG polarization
In T cells, the increase in cytosolic free Ca2+ concentrations ([Ca2+]i) plays a
major role in the activation of LFA-1. Eliciting cytosolic Ca2+ elevation by ionomycin or
stimulating CD3 was capable of directly activating LFA-1 (70). It has been reported that
both anti-CD11a and anti-CD18 can prolong the Ca2+ response induced by anti-CD3
(71) . More importantly, aggregation of the intact cytoplasmic domain of integrin β2 was
sufficient to trigger Ca2+ transients in Jurkat cells, which was abrogated in T cells that
do not express the T cell receptor (72).
However, it remains controversial whether cytosolic Ca2+ rise is involved in LG
polarization and NK cell activation. First, although the activation of LFA-1 by antibodies
did not trigger any Ca2+ response in NK cells, it is sufficient to induce LG polarization
to NK IS (69). Second, despite that ORAI1 channels were triggered following
stimulation of activating receptors (73), LG polarization is not affected in NK cells from
patients with ORAI1 mutation in which SOCE is largely impaired (44). On the other
hand, my current data from chelation of intracellular Ca2+ with BAPTA indicate that a
rise in intracellular Ca2+ is essential for LG polarization in NK cells. It is possible that
some important proteins in the integrin ‘outside-in’ signaling pathway require Ca2+ for
- 49 -

their normal functions and these may be interrupted by BAPTA.
Therefore, the relations between the integrin ‘outside-in’ signaling and
intracellular Ca2+ responses need to be examined more carefully. It would be
interesting to test whether co-activation of LFA1 with activating receptors might
enhance the Ca2+ response in NK cells as compared to that induced by activating
receptors alone. Importantly, whether there is actually a Ca2+ response in the cellular
system of LFA-1 activation (conjugation of NK with S2 cells expressing ICAM1) needs
to be tested carefully.
Irrespective to whether the Ca2+ signal is required for LG polarization or not, it
has long been reported that inhibitory receptors can block the Ca2+ response in
lymphocytes (74). Here, I also found that PD-1 engagement abolished the Ca2+
response triggered by activating receptors NKG2D and CD16, consistent with the
finding in T cells where PD-1 signaling blocked the Ca2+ response triggered by TCR
activation (75). It is quite clear that Ca2+ should be crucial for degranulation since LG
exocytosis requires Ca2+ (76). Thus, the blockade of Ca2+ signaling by PD-1 in NK cells
would further suppress the cytotoxicity of these cells.

2.4.4 Exchange of PD-1 and PD-L1 in NK and target cells
During the course of this study, I observed an interesting phenomenon that the
GFP signal of PD-1 transferred into the target cells while the mCherry signal of PD-L1
translocated to NK cells after long-term (16 hr) conjugation (Figure 23), indicating that
these cells may exchange their contents in the presence of PD-1 signaling. Receptor
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transfer has been studied by other groups in different models (77, 78); however, the
underlying mechanisms and the physiological significance of this phenomenon remain
largely unexplored. It is possible that the exchange for PD-1 and PD-L1 between
effector and target cells is caused by the direct binding between these two proteins.
Interestingly, it was found that there are polarized release of TCR-enriched microvesicles at the IS recently (79).

Figure 23. Exchange of PD-1 and PD-L1 between NK and target cells after long-time
conjugation. Live-cell imaging of NK-PD-1-GFP cells (green) conjugated with the target
K562-PD-L1-mCherry cells or K562-mCherry (red). Images were taken by confocal
microscopy at 16 hr after conjugation. Scale bars: 5 μm.
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Previously,

Jewett and

Bonavida have reported that the levels of

CD16/CD2/CD56 in NK cells were decreased after conjugation with K562 cells. In the
sorted NK cells after the conjugation, the cytotoxic activity were also found to be
decreased (80). However, after dissociation with K562 or other target cells NK cells
still maintain certain degree of cytotoxic activity especially in the presence of IFNα
and/or IL2 (80, 81). Indeed, it was shown that a single NK cell could kill up to 10 targets
over a 6-hr period (82). Thus, I hypothesize that in addition to inhibiting LG
polarization/degranulation and calcium signaling, the PD-1 receptor and its ligand, PDL1, may be also able to further down regulate the post-conjugation functions of NK
cells and thereby inhibit the serial killing by these cells. The above observed transfer
may then explain why PD-L1 was found in tumor infiltrating lymphocytes and could
serve as a prognostic marker in some cancers (83).

In conclusion, I investigated the role of PD-1 in NK cell-mediated cytotoxicity,
which revealed the underlying molecular basis of the inhibitory receptor PD-1 in NK
cell immune responses. Although PD-1 expression is limited in NK cells from healthy
individuals, it is upregulated in NK cells from patients with a variety of chronic diseases
(9, 10, 84, 85). I found that PD-1 engagement by its natural ligand, PD-L1,
preferentially blocks LG polarization via specifically impairing the polarization of the
central integrin signaling molecule of lymphocytes, ILK, at the NK cell IS. This study
uncovers a novel, common master signaling molecule used by PD-1 inhibitory receptor
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in human NK cells, which should shed lights on harnessing the power of NK cells by
targeting a downstream PD-1 signaling molecule for disease treatment in the future.
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Chapter 3

RIP3 dependent necroptosis is involved in acidosis induced cell death via
MLKL & AIF
3.1 Background
3.1.1 Ischemic stroke
Stroke is the 5th leading cause of death in the US, with one person dying every
4 minutes as a result of stroke. Strokes occur to approximately 800,000 people each
year in the US alone, which is equivalent to about one every 40 seconds (86). However,
to date, no effective treatment is available for this disease. A stroke often damages
brain because it causes a sudden interruption of the blood supply to the brain. The
brain damage leads to long lasting neurological deficits in stroke patients, severely
impairing the patients’ quality of life.
There are two types of stroke, hemorrhagic and ischemic. Between the two,
hemorrhagic stroke is less common and is caused by bleeding into the brain tissue
when a blood vessel bursts. Blood spills into or around the brain and creates swelling
and pressure, damaging cells in the brain. Ischemic stroke accounts for about 87
percent of all stroke cases. It occurs when a blood vessel carrying blood to the brain
is blocked by a blood clot. Currently, the only FDA approved drug to treat ischemic
stroke is the thrombolytic agent tissue plasminogen activator (tPA), which is supposed
to re-open the clotted vessels. However, this approach has very limited success due
to the short therapeutic time window of 3 to 4.5 hours of the first symptoms and side
effect of intracranial hemorrhage (87). For people with blood clots in larger arteries,
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tPA often does not dissolve them completely.
Several key players in ischemic cell death have been identified, including
excitotoxicity, oxidative and nitrosative stress, and inflammation; however, numerous
clinical trials have failed to show efficacy of drugs that modulate these mechanisms in
patients, despite promising preclinical data (88). Consequently, there is a pressing
need for identifying new ways to treat patients with ischemic stroke (86).
3.1.2 Acidosis and acidotoxicity
Acidosis is an increased acidity in the blood and other body tissues. It occurs
commonly under pathological conditions when the body homeostasis is disrupted due
to inflammation, hypoxia, cancer and other illnesses.
Acidosis is a common feature in cancer. Due to the higher metabolic activity and
limitations in blood flow (hypoxia) in tumors, the microenvironment around them tends
to be more acidic, reaching pH values of 6.2-6.8 (89, 90). However, hypoxia and
oncogene activation also allow cells to adapt to the potentially toxic effects of an excess
in acidosis. Hypoxia does so by inducing the activity of a transcription factor the
hypoxia-inducible factor-1 (HIF-1), which in turn enhances the expression of a number
of intracellular pH regulating systems that cope with acidosis (91). Thus, cancer cells
adapt quite well and even thrive in acidity.
On the other hand, acidosis is detrimental to neurons. Acidosis is commonly
associated with many central nervous system diseases and neurodegenerative
diseases such as seizure (92), Alzheimer’s disease (AD) (93), Parkinson’s disease
(PD) (94) and Huntington’s disease (HD) (93, 95). Tissue acidosis is also another well- 55 -

characterized feature that contributes to brain injury during cerebral ischemia. The
normal brain requires complete oxidation of glucose to fulfill its energy requirements.
During ischemia, oxygen depletion forces the brain to switch to anaerobic glycolysis.
The accumulation of lactic acid as a byproduct of glycolysis and protons produced by
ATP hydrolysis cause the extracellular pH to fall in the ischemic brain, typically to 6.5–
6.0 during ischemia under normoglycemic conditions, or even below 6.0 during severe
ischemia (96-98). It seems that neurons do not have the capability to handle this
sudden drop of pH like tumors do. Acidosis often causes neuronal death and thus it
was given a special term called “acidotoxicity”. Although the signaling mechanisms of
acidotoxicity remains mysterious, early studies have shown that acid-sensing ion
channel type 1a (ASIC1a) plays a critical role in acid-induced neuronal cell death and
genetic deletion or pharmacological blockade of ASIC1a is protective against brain
damage associated with ischemic stroke in rodent models (98).

3.1.3 Acid-sensing ion channel
Acid-sensing ion channels (ASICs) are voltage-insensitive Na+ channels
activated by external protons (H+). These channels belong to the epithelial sodium
channels/ degenerin (ENaC/Deg) ion channel superfamily. They were first cloned and
shown to be widely distributed in the nervous system by Michel Lazdunski group in
1997 (99). In mammals, there are six distinct ASIC isoforms (ASIC1a, ASIC1b, ASIC2a,
ASIC2b, ASIC3, and ASIC4) encoded by four different genes (ACCN1–4). All ASICs
except AISC1b are expressed in the central nervous system and all of them are
present in the peripheral nervous system. ASICs are formed by combinations of ASIC
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subunits in homotrimeric or heterotrimeric complexes. Recently, ASIC5 was reported
as a new member of the ASIC family. However, ASIC5 is very divergent from other
family members. It forms an ion channel that is insensitive to H+ but is sensitive to bile
acids. Therefore, it is also named as bile acid-sensitive ion channel (BASIC) (100).
ASICs have been extensively studied and implicated to play important roles in
many physiological functions and pathological conditions (101). These include, for
examples, learning and memory (102), fear conditioning (103), pain (104), seizure
(105), PD (106), HD (107) and so on. Therefore, targeting ASICs may provide novel
and effective therapeutic interventions for a number of diseases.
Among the ASIC isoforms, ASIC1a is predominantly expressed in brain neurons
and critically involved in acidosis-induced neuronal cell death both in vitro and in vivo
(98, 108). Either gene ablation of ASIC1a or administration of an ASIC1a inhibitor,
psalmotoxin 1 (PcTX1), even at up to 5 hrs after the onset of brain ischemia and during
reperfusion, protected against the brain damage in the mouse model of ischemic stroke
(98, 108). These suggest that ASIC1a is involved in delayed ischemic brain injury and
a plausible therapeutic target for mitigating ischemic brain injury. However, PcTX1 is
unsuitable to stroke therapy due to low blood-brain barrier permeability and poor
stability. The potential on-target side effect on the normal physiological function of
ASIC1a also cannot be ignored. Thus, elucidating the downstream mechanism(s) of
ASIC1a-mediated neuronal death will help identify new strategies to target this
pathway.
Much of the previous work on ASICs and neurotoxicity/acidtoxicity focused on
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ASIC1a homotrimeric channels since they are able to conduct Ca2+ and induce Ca2+mediated toxicity (98, 109). Importantly, disrupting the gene encoding ASIC1a in mice
eliminated most of the current evoked by extracellular acid in CNS neurons, suggesting
that ASIC1a is a critical channel subunit (98, 102). However, the Ca2+ permeability of
ASIC1a channels is relatively small comparing to other Ca2+-permeable channels, and
the increased influx of Ca2+ occurs only for seconds in response to acidity.
Recently, my colleagues and I showed that extracellular protons trigger a novel
form of neuronal death, necroptosis, via ASIC1a, independent of the channel’s ionic
conducting function (110). We identified receptor-interacting serine/threonine-protein
kinase 1 (RIP1) as a critical component of this form of neuronal necroptosis. Following
acid stimulation of primary cultured neurons in vitro and brain ischemia in a mouse
stroke model in vivo, RIP1 became physically associated with ASIC1a and then
phosphorylated. Inhibiting RIP1 with its inhibitor, Nec1, protected neurons from
acidosis-induced neuronal death (111). However, the downstream changes associated
with ASIC1a-mediated RIP1 phosphorylation during acidosis remain to be illustrated.

3.1.4 Necroptosis and Parthanatos
Necroptosis is a form of programmed necrosis, which was dubbed by Junying
Yuan’s group in 2005 (111). Necrosis has been considered as an uncontrollable
accidental cell death for a long time. However, it is now clear that necrosis can also
occur in a regulated manner. Differently from apoptosis, the morphological
characteristics of necrosis /necroptosis include swelling of organelles, plasma
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membrane rapture and subsequent loss of intracellular contents.
The term “necroptosis” was firstly introduced to indicate a tumor necrosis factor
receptor 1 (TNFR1) ligation induced regulated necrosis and it can be inhibited by the
RIP1 inhibitor necrostatin-1 (Nec1) (111). In fact, before the nomenclature was
proposed, a number of studies had shown that caspase inhibition did not block death
receptor (DR) agonist–induced cell death but rather led it to necrosis (112-114). After
its naming, our understating of molecular mechanisms underlying necroptosis has
progressed significantly. It has been well established that conventional necroptotic
pathway involves the formation of necrosomes containing RIP1 and its downstream
effectors RIP3 and MLKL. Upon phosphorylation by RIP3, MLKL plays a critical role in
necroptosis. The phosphorylated MLKL forms oligomers that translocate to cellular
membranes (including the plasma membrane) and results in the loss of barrier function
(115, 116).
Parthanatos, coined in a review article in 2009 after the personification of death
in Greek mythology Thanatos, is a new class of cell death (117). The NCCD classifies
it to be one form of RCD other than necroptosis (1). In parthanatos, oxidative damage
to DNA results in activation of poly(ADP-ribose) polymerase (PARP) and generation of
poly(ADP-ribose) polymers (PAR polymers) that trigger release of mitochondrial
apoptosis-inducing factor (AIF) and its translocation to the nucleus (117). Recently, a
study showed that parthanatos is one of the mechanisms by which ischemiaassociated tissue acidosis augments cell death. The authors showed that acidosis
augmented the formation of PAR polymers, the nuclear translocation of AIF, and
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neuronal cell death (118).
Both necroptosis and parthanatos play critical roles in many pathophysiological
processes including ischemic injury (111, 119). Although we have shown

that

acidosis triggers necroptosis via ASIC1a and RIP1 (110), the downstream signaling
steps of acid-induced necroptosis have yet to be elucidated. It is reasonable to expect
that RIP3 and/or MLKL is also required for acidosis induced cell death. We also
hypothesize that acidosis induced cell death may share some common features with
parthanatos. Both of these possibilities were tested in this study. Elucidating the
mechanism(s) underlying ASIC1a-mediated neuronal damage will significantly impact
our knowledge on neuronal acidotoxicity and help devise new strategies to combat
neurological damage caused by ischemic stroke.
In this study, I investigated mechanisms underlying ASIC1a-mediated neuronal
damage. I show that RIP3 and MLKL, known to be downstream of RIP1 in necroptosis,
are also required for acidosis-induced cell death, in which serum starvation is a critical
contributing factor. Although acidosis/starvation-induced cell death is different from
parthanatos, AIF translocation is also involved as a downstream event of RIP3
activation. The AIF nuclear translocation due to acidosis/ starvation is facilitated by
mitochondrial permeability transition pore (MPTP) and reactive oxygen species (ROS).
Inhibiting RIP3 reduced both acid-induced death of mouse cortical neurons in vitro and
brain infarction in mice elicited by MCAO in vivo by the FDA approved anti-cancer drug
Dabrafenib.
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3.2 Materials and methods
3.2.1 Cell lines and mouse cortical neuron culture
Neuro-2a (N2a), Human Embryonic Kidney 293 (HEK293) and mouse
embryonic fibroblast cells were maintained in DMEM (high glucose) with 10% FBS,
100 units/ml penicillin and 100 µg/ml streptomycin at 37°C, 5% CO2. For experiments
where transient expression was used, cells were transfected using Lipofectamine 2000
and used for experiments after 16-20 hours.
For primary culture of mouse cortical neurons, brains from postnatal day 1 wild
type C57BL/6 mice were removed rapidly and placed in ice-cold calcium, magnesium
free Hank's Balanced Salt Solution (HBSS). Tissues were dissected and incubated
with 0.05% trypsin-EDTA for 30 min at 37˚C. HBSS with 10% FBS was used to
terminate the digestion process and cells were triturated with a 10-ml pipette. Cells
were filtered through a 70 micron strainer, resuspended in the culture medium (see
below), and plated in poly-D-lysine-coated 10-cm culture dishes or 96-well plates (1 ×
107 cells per dish, 5 × 104 cells per well). Neurons were cultured in Neurobasal medium
supplemented with B27, 2 mM L-glutamate (ThermoFisher Scientific, USA) and
maintained at 37˚C 5% CO2 in an incubator. The medium was half changed twice a
week and the neurons used for assay 14–16 days after plating. Glial growth was
suppressed by the addition of 5-fluoro-2-deoxyuridine (20 μg/ml; Sigma–Aldrich, USA)
and uridine (20 μg/ml; Sigma–Aldrich, USA).
3.2.2 Cell death assay
Acid and starvation induced cell death was achieved as previously described
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(110). Briefly, cells were washed once within 5 minutes at room temperature with the
treatment extracellular solution (ECS, contains 140 mM NaCl, 2 mM CaCl2, 5 mM KCl,
1 mM MgCl2, 10 mM Glucose, 10 mM HEPES), of which the pH was either adjusted to
7.4 or 6.0. Then, they were incubated at 37 ˚C for 1 hr in the same pH 7.4 or pH 6.0
ECS. At the end of the treatment, the solution was replaced with the normal pH culture
medium and the culture resumed at 37 ˚C. Primary cultured neurons were recovered
for 24 hr and N2a cells were recovered for 7 hr due to their ability of fast proliferation.
For treatment where inhibitors were used, the neurons were pre-incubated with the
drug for 30 minutes in the medium and co-incubated with the pH 7.4 or pH 6.0 ECS for
1 hr. For inhibitor treatment of N2a cells, the drug was applied together with the ECS
for 1 hr and present in the culture medium throughout the 7-hr recovery time. The
sources and concentrations of all pharmacological reagents used are listed in Table 1.
Cell death was assessed using multiple methods: Cell Titer Blue (CTB), lactate
dehydrogenase (LDH) measurement and SYTOXBLUE staining assay. For CTB assay,
cells were cultured in the wells of 96-well plates and acid-treated as described above.
Then, 20 μl CTB solution (Promega, USA) was added to each well and the plates were
incubated for 4 hrs at 37 ˚C. The fluorescence intensities (excitation 560 nm, emission
590 nm) were measured by the FlexStation Microplate Reader. For LDH assay, the
LDH release was measured in the culture medium using the LDH assay kit (Takara Bio,
USA). Briefly, 100 μl of the culture medium was transferred from the culture wells to
wells of a 96-well plate and mixed with 100 μl of the reaction solution provided by the
kit. Optical density was measured at 492 nm 45 min later, using a microplate reader
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(Spectra Max Plus, Molecular Devices). Background absorbance at 620 nm was
subtracted. For SYTOXBLUE staining, cells were stained with 0.5 μM SYTOXBLUE
(Invitrogene, USA) for 10 minutes in an incubator and then examined by fluorescence
microscopy (Leica).
Table 1. Reagents used for cell death assay
Name

Description

Concentration

Company

PcTX1

AISC1 blocker

50 nM

Millipore

Nec1

RIP1 inhibitor

40 μM

Cayman Chemical

GSK’872

RIP3 inhibitor

3 μM

APExBIO

Dabrafenib

RIP3 inhibitor

10 μM

Cayman Chemical

TNFα

Death receptor ligand

30 ng/ml

Millipore

Smac mimetic

IAP antagonist

100 nM

TOCRIS

z-VAD

Caspase inhibitor

20 nM

APExBIO

DIDS

VDAC inhibitor

500 μM

ANASPEC

TRO19622

VDAC inhibitor

20 μM

TOCRIS

NAC

antioxidant

6 mM

Oakwood chemical

TEMPOL

antioxidant

500 μM

Enzo

Trolox

antioxidant

100 μM

ACROS

ALLN

Calpain inhibitor

10 μM

APExBIO

DPQ

PARP inhibitor

30 μM

Cayman Chemical
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3.2.3 Knocking down of mouse MLKL
Two plasmids that contain shRNA for mouse MLKL were purchased from Sigma.
Their

targeting

sequence

are:

“CCGGAGATCCAGTTCAACGATATATCTCGA

GATATATCG-TTGAACTGGATCTTTTTTG” and “CCGGTCCCAACATCTTGCGTATA
TTCTCGAGA-ATATACGCAAGATGTTGGGATTTTTG”. A negative control plasmid
was kindly provided by Dr. Guangwei Du (University of Texas Health Science Center
at Houston). Assays were performed 2 days after transfection and the efficiency of
knocking down was assessed by Western blotting.

3.2.4 Patch clamp electrophysiology
Acid-evoked currents were recorded using whole-cell patch-clamp recording
techniques at room temperature (22–25˚C). For the voltage-clamp recordings, the
membrane voltage was held at −60 mV. The standard external solution (SS) contained:
150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, and 10 mM glucose, buffered to
various pH values with 10 mM HEPES. The patch pipette solution contained: 120 mM
KCl, 30 mM NaCl, 1 mM MgCl2, 0.5 mM CaCl2, 5 mM EGTA, 4 mM Mg-ATP, and 10
mM HEPES, pH 7.4. The osmolarity of all solutions was kept at 300–330 mOsm/l.
Voltage commends and current recordings were controlled by an EPC10 amplifier with
the use of the PatchMaster program. Currents were recorded continuously at 10 kHz.

3.2.5 Co-immunoprecipitation
N2a cells under different treatment were collected and re-suspended in a lysis
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buffer containing 20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA,
3 mM NaF, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 2 mM Nethylmaleimide, 10% glycerol, protease inhibitors (Roche, Switzerland) and
phosphatase inhibitors (Sigma, USA). The re-suspended lysates were vortexed,
incubated on ice for 30 min, and centrifuged at 13000Xg for 15 min at 4°C. The
supernatant was incubated with 2 μg primary antibody overnight at 4°C. The primary
antibodies used were mouse monoclonal mCherry antibody (Biolegend) or rabbit
polyclonal MLKL antibody. Protein A sepharose beads (Roche) were added to the
samples and incubated for 2 hrs at 4°C in the following day. Beads were then washed
5 times with the lysis buffer before elution with 2X SDS sample buffer containing 10%
β-mercaptoethanol at 95 °C for 5 min. The eluted proteins were subject to SDS-PAGE
and Western blotting.

3.2.6 Immunoblotting (Western blotting)
Protein samples were separated by SDS-PAGE and transferred to
polyvinylidene fluoride (PVDF, Thermo Scientific) or nitrocellulose membrane (LI-COR
Inc., USA). The membrane was blocked with a blocking buffer (5% milk/0.1% Tween20 in PBS) for 1 hr at room temperature and then incubated at 4°C overnight with the
primary antibody. The primary antibodies were used at the following dilutions: rabbit
anti-RIP1 (1:500, BD), rabbit anti-RIP3 (1:500, Cell Signaling Technology, CST), rabbit
anti-MLKL (1:500, CST), rabbit anti-pRIP3 (1:500, CST), rabbit anti-pMLKL (1:500,
Abcam), mouse anti-mCherry (1:1000, Biolegend), rabbit anti-LC3 (1:1000, Sigma),
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rabbit anti-IkBa (1:1000, CST), rabbit anti-AIF (1:1000, CST), chicken anti-ASIC1a
(1:1000, Santa Cruz) and mouse anti-Actin (1:3000, Santa Cruz. After washing 3 times
with a washing buffer (0.1% Tween-20 in PBS), the membrane was incubated with
HRP-conjugated secondary antibodies (1:10000, Roche) or IRDye® secondary
antibodies (1:10000, LI-COR Inc.) for 1 hr at the room temperature. After extensive
washes with the washing buffer, the blots were visualized by exposure to ECL reagent
(Thermo Scientific) when HRP-conjugated secondary antibodies were used or with the
use of Odyssey® CLx imaging system (LI-COR Inc.) when IRDye® secondary
antibodies were used.

3.2.7 Immunocytochemistry
N2a cells were grown on poly-L-ornithine coated coverslips and subject to
different treatments as described. The samples were washed once with PBS and cells
fixed with 4% paraformaldehyde in PBS for 10 min. The fixed cells were washed 3
times with PBS and permeabilized with PBS containing 0.1% Triton X-100 and 5%
bovine serum albumin (BSA) for 1 hr at 37°C before incubation with the primary AIF
antibody (1:300, CST) at 4°C overnight. The cells were washed and probed with the
fluorophore-conjugated secondary antibody (Invitrogen, USA) at room temperature
for 1.5 hours. Then, the cells were incubated with DAPI (300 nM) solution for 15 min
before being mounted by the ProLong Gold antifade reagent (Life Technologies, USA).
Slides were examined by fluorescence microscopy (Olympus) and images were
analyzed and processed by ImageJ software.
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3.2.8 Focal ischemia
The surgery was done by our collaborators in China and the experimental
protocols (ethics protocol number: 2014022) were approved by the Animal Care and
Use Committee of Shanghai Jiao Tong University School of Medicine, Shanghai, China.
A transient focal ischemia model was prepared as described previously (110, 120) via
suture occlusion of the middle cerebral artery (MCAO) in male wild type and ASIC1a-/C57BL/6 mice (~25 g). Briefly, animals were anesthetized using 10% chloral hydrate
with intubation and ventilation. Rectal and temporalis muscle temperature was
maintained at 37 ± 0.5˚C with a thermostatically controlled heating pad and lamp. A
suture occlusion was made to the middle cerebral artery while cerebral blood flow (CBF)
was monitored by transcranial laser Doppler. Animals whose blood flow did not reduce
below 20% were excluded. The suture was removed 1 hr after MCAO to allow
reperfusion and the mice were euthanized 24 hrs later. Brains were removed,
sectioned coronally at 1 mm intervals, and stained with the vital dye 2,3,5triphenyltetrazolium hydrochloride (TTC).
Intracerebroventricular injection was performed by stereotaxic technique using
a microsyringe pump as described previously (120). For each animal, 5 µl of artificial
cerebrospinal fluid (aCSF), or 5 µl aCSF containing 2.5 µg Dabrafenib (Cayman
Chemical Company, USA) was injected 30 min after reperfusion.

- 67 -

3.2.9 Statistical analysis
Statistical comparisons were performed by Prism software (GraphPad Software,
Inc.) using unpaired or paired Student’s t test where values of p<0.05 are considered
significant.

3.3 Results
3.3.1 RIP3 is involved in acidosis-induced neuronal cell death
We have previously demonstrated that acidosis-induced neuronal cell death is
ASIC1 and RIP1 dependent. Since RIP3 is phosphorylated by RIP1 kinase and
represents another critical kinase responsible for mediating necroptosis, I examined
the role of RIP3 in acidosis-induced neuronal cell death. I first examined the
phosphorylation of RIP3 in primary cultured mouse cortical neurons treated with either
a pH 7.4 extracellular solution (ECS) or a pH 6.0 ECS for 1 hr, followed by recovery in
the normal medium for another hr. Using a phospho-RIP3 (p-RIP3) antibody, I detected
an increase in the p-RIP3 level in the pH 6.0-treated samples (Figure 24A). Because
the antibody for total RIP3 did not work well for mouse cortical neuron samples, I used
actin as the loading control for this experiment.
To test if RIP3 activity was required for pH 6.0-induced neuronal death, I used
GSK’872 and dabrafenib, two recently reported RIP3 inhibitors (121). For this, the
neurons were treated with pH 7.4 and pH 6.0 ECs for 1 hr, which was then followed by
recovery in the normal culture medium for 24 hrs before cell viability was measured
using the CTB assay. Under these conditions, typically about 60-70% neurons die as
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a result of the pH 6.0 treatment. To validate the inhibitors, I also treated HT29 cells, a
human colorectal adenocarcinoma cell line frequently used to study necroptosis (122),
with a mixture of TNFα, smac mimetic, and Z-VAD (TSZ) as an established in vitro
model of necroptoic death that requires RIP3 activity. Indeed, both GSK’872 and
dabrafenib blocked the death of HT29 cells triggered by the treatment with TSZ for 24
hrs, and the RIP1 inhibitor Nec-1 exerted protection (Figure 24B). Similarly, GSK’872
and dabrafenib (added at 30 min prior to the acid treatment and not included during
the recovery period) also protected the cultured cortical neurons from acidosis-induced
death to a similar degree as Nec-1 and the ASIC1a inhibitor, PcTX1 (Figure 24C).
These results demonstrate that RIP3 is involved in the acidosis-induced neuronal
death.
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Figure 24. RIP3 is involved in acidosis-induced neuronal cell death. (A) Western blot
analysis of phospho-RIP3 levels in lysates from mouse cortical neurons untreated (/) or treated
pH 7.4 or pH 6.0 ECS for 1 hr then recovered in the normal medium for another hr. Actin was
used as loading control. (B) HT29 cells were treated with TSZ (TNFα: 30 ng/ml, Smac mimetic:
100nM, z-VAD: 20nM), or TSZ with Nec-1 (40μM), dabrafenib (10μM), or GSK’872 (3 μM)
for 24 hrs. The viability of cells was determined by the Cell-Titer Blue (CTB) assay. (C)
Cultured mouse cortical neurons were pretreated with DMSO, PcTX1 (50 nM), Nec-1 (40μM),
GSK’872 (3 μM), or dabrafenib (10 μM) for 30 min and then incubated with pH 7.4 or pH 6.0
ECS for 1 hr. Neurons were recovered for 24 hrs in normal medium before cell viability was
performed using the CTB assay. Results are representative of three independent experiments.
Error bars represent SDs. *, P＜0.05 vs. untreated (B) or pH 6.0 with DMSO (C).
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3.3.2 Re-introduction of RIP3 increases cell death in response to acidosis
The failure of the commercial antibody to detect total RIP3 proteins in primary
cortical neurons prompted me to search for suitable cell lines to study acidosis-induced
cell death. Notably, many cell lines are resistant to acidosis-induced death. It turns out
that these cells either lack AISC1a, for example, HT29, COS7, Chinese hamster ovary
(CHO) cells; or they do not express RIP3, such as N2a and HEK293 (Table 2).
Previous studies have shown that exogenously expressing AISC1a in COS7 and CHO
cells can recapture the acidosis-induced cell death (98, 123). However, it was not
known whether reintroduction of RIP3 in the RIP3-negative cells would rescue the acid
sensitivity. More interestingly, RIP3 expression has been shown to be lost in many
cancers and this may be responsible for their resistance to death in the acidic tumor
microenvironment (124).

Table 2. Different acid sensitivity of various cells. The expression of ASIC1a and RIP3 in
different cells is indicated by “+” (positive) and “-” (negative). Their sensitivity to acid-induced
death is indicated by the √ and × signs.
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To test whether heterologous expression of RIP3 can recapture acidosisinduced cell death, I first tried HEK293 cells. GFP-tagged human RIP3 (hRIP3-GFP)
or mCherry-tagged mouse RIP3 (mRIP3-mCherry) were expressed in HEK293 cells
by transient transfection and the expression was confirmed by Western blotting. GFP
tag only was used as a negative control (Figure 25). Treatment with TSZ killed cells
that expressed hRIP3 but not those that expressed GFP or mRIP3. Similarly, cells that
expressed hRIP3 also became sensitive to 1 h treatment with the pH 6.0 ECS (with 24
hrs of recovery in the normal medium) as compared to pH 7.4 ECS. By contrast,
several attempts by introducing mRIP3 to the HEK293 cells failed to confer the
sensitivity to pH 6.0 ECS (Figure 26, 27). This is consistent with a previous report that
there is species specificity for the RIP3-MLKL interaction, where human RIP3 does not
interact with mouse MLKL and mouse RIP3 cannot bind to human MLKL (125). As
such, the mouse RIP3 expressed in the human cells is not expected to form
necrosomes for necroptotic cell killing.
The results in HEK293 cells indicate that RIP3 may play a pivotal role in both
TSZ- and acidosis-induced necroptosis. However, in both CTB (Figure 26) and LDH
(Figure 27) assays, the difference between pH 7.4- and pH 6.0-treated hRIP3expressing cells was moderate. Importantly, the treatment with pH 7.4 ECS already
triggered marked cell lose as compared the control (in normal culture medium,
untreated). This suggests that HEK293 cells may be very sensitive to starvation, which
can compromise our ability to detect acid-induced RIP3-dependent necroptosis.
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Figure 25. Verification of RIP3 expression in HEK293 cells. After transfection with the
corresponding plasmids, the expression of GFP-tagged human RIP3 (hRIP3, upper) or
mCherry-tagged mouse RIP3 (mRIP3, middle) was assessed in cell lysates by Western blotting
using hRIP3 and mRIP3 antibodies, respectively. Actin was used as the loading control.
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Figure 26. hRIP3 expression confers TSZ-induced cell death and differential responses to
pH 7.4 and pH 6.0 ECS, as determined by CTB assay. The viability of HEK293 cells that
expressed GFP (A), mouse RIP3 (B) or human RIP3 (C) and were treated with normal culture
medium (/), TSZ (24 hrs), or pH 7.4 or pH 6.0 ECS (1 hr treatment plus 24 hr recovery in
normal medium) was assessed by CTB assay. Error bars represent SDs. NS, Not significant. *,
P＜0.05.
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Figure 27. hRIP3 expression confers TSZ-induced cell death and differential responses to
pH 7.4 and pH 6.0 ECS, as determined by LDH assay. LDH release from HEK293 cells that
expressed GFP (A), mouse RIP3 (B) or human RIP3 (C) and were treated with normal culture
medium (/), TSZ (24 hrs), or pH 7.4 or pH 6.0 ECS (1 hr treatment plus 24 hr recovery in
normal medium) was assessed by LDH assay. Error bars represent SDs. NS, Not significant.
*, P＜0.05.
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N2a is a fast-growing mouse neuroblastoma cell line, which had been used for
the study of acidosis-induced cell death before. However, the percentage of death
reported was very low (around 15%) under 1 hr pH 6.1 treatment (126). Indeed I did
not detect any obvious cell death in wild type N2a cells after the treatment with pH 6.0
ECS (Figure 28A). Since RIP1, RIP3 and MLKL are thought to be important
necroptosis effector molecules (122) and ASIC1 is required for the acid-induced death
(98), I checked the expression of ASIC1, RIP1, RIP3 and MLKL in N2a cells by Western
blotting. While ASIC1a, RIP1 and MLKL were detected in N2a cells, RIP3 was not
(Figure 28B). As a control, RIP3 was detected in mouse embryonic fibroblasts (Figure
28B). Interestingly, the mouse embryonic fibroblast cells were insensitive to acidosisinduced death (data not shown); however, this may be due to the fact that they do not
express AISC1 (Figure 28B). Using whole-cell patch clamp recordings, we were able
to detect ASIC-like inward current evoked by the pH 6.0 ECS at the -60mV holding
potential in N2a cells (Figure 28C). Therefore, N2a cells express ASIC1 but not RIP3,
explaining their resistance to acid-induced death.
I then transfected the N2a cells with mCherry-tagged mouse RIP3 (mRIP3mCherry) to see whether reintroduction of RIP3 could recapture acidosis-induced
death in these cells (Figure 28D). Comparing to mCherry, the expression of mRIP3mCherry significantly increased the percentage of dead cells in response to 1 hr pH
6.0 treatment based on the SYTOXBLUE staining (Figure 28E, F), which specifically
labels dead cells. In N2a cells that were untransfected or transfected with mCherry, the
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treatment with pH 7.4 ECS did not trigger any obvious cell death and their response to
the pH 6.0 ECS was quite moderate (less than 3%). However, following the expression
of mRIP3-mCherry, the percentage of cell death went up to around 10% even in cells
exposed to pH 7.4 ECS and this value was further increased to around 40% with the
treatment of pH 6.0 ECS.
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Figure 28. Re-introduction of RIP3 increases acidosis-induced death of mouse
neuroblastoma N2a cells. (A) N2a cells were treated with pH 7.4 or pH 6.0 ECS for 1 hr and
then recovered in the normal culture medium for 24 hrs. The viability of cells in each group
was determined by CTB assay. (B) Protein expression levels of ASIC1, RIP1, RIP3, MLKL,
and actin in N2a and MEF cells were tested by Western blotting. (C) ASIC-like acid-induced
current recorded at -60 mV from a N2a cell. Representative trace of n=6 cells. (D) The
expression of mCherry, and RIP3-mCherry after transfection in N2a cells was confirmed by
Western blotting using mCherry (lower) and mRIP3 (upper) antibodies. (E) N2a cells
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transfected with mCherry or mouse RIP3-mCherry were treated with pH 7.4 or pH 6.0 ECS for
1 hr and then recovered in the normal medium for 7 hr. Cells were stained with SYTOXBLUE
to reveal dead cells and images were taken by fluorescence microscope. Scale bar: 30 μm. (F)
Quantification of percentages of SYTOXBLUE-positive cells as in (E). Error bars represent
SDs. NS, Not significant. *, P＜0.05.

3.3.3 MLKL is involved in acidosis-induced cell death in N2a-RIP3 cells
MLKL is another important component of necrosomes. I examined the
phosphorylation of MLKL during and after acid stimulation of N2a cells that expressed
mRIP3. Consistent with the idea that MLKL phosphorylation by RIP3 kinase is critically
involved in necroptosis, increased levels of phospho-MLKL were detected during the
first hr of the pH 6.0 ECS treatment but the increase subsided 1 hr of returning to the
normal medium. The total MLKL levels remained unchanged during the time period
(Figure 29 A, B). Furthermore, it is well-established that RIP3 and MLKL co-exist in
the same protein complex, i.e. necrosomes, during necroptosis (125). To test if this is
also the case for acidosis-induced necroptosis, I performed co-IP to check if RIP3
became physically associated with MLKL in response to acid treatment. I found that in
the pH 6.0 ECS treated samples, the amount of RIP3 that co-IPed with MLKL was
markedly higher than that incubated with pH 7.4 ECS (Figure 29C). Reciprocally, the
amount of MLKL that co-IPed with mCherry (for RIP3) was also more in pH 6.0 treated
than in pH 7.4 treated samples (Figure 29C). These data indicate that the association
between RIP3 and MLKL was increased in response to the acid treatment, consistent
- 79 -

with that happened in the classical necroptosis triggered by TNF. The activated MLKL
could be responsible for the demise of cells exposed to the acidic environment.
Next, I tested the effect of knocking down MLKL expression on the acidosisinduced death of N2a cells that expressed RIP3. Two shRNA constructs targeting
mouse MLKL and a control shRNA construct were transfected together with mRIP3 in
N2a cells. At 48 hrs after transfection, MLKL protein levels in the MLKL shRNA groups
decreased to 29% and 38% of the control shRNA group (Figure 30A). After treatment
with pH 6.0 ECS for 1 hr, followed by 7 hr recovery in normal medium, cell viability was
assessed by SYTOXBLUE staining. Both MLKL shRNA resulted in protection of the
N2a cells from the acidosis-induced death, as shown by the reduced percentage of
SYTOXBLUE-positive cells (Figure 30B).
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Figure 29. MLKL is involved in acidosis-induced cell death. (A) Schematics of treatment
conditions. N2a cells expressing RIP3 were treated with pH 7.4 or pH 6.0 ECS for 1 hr and
then recovered in the normal culture medium for another hr. (B) Cells were collected at different
time points as indicated and assessed by Western blotting for phospho MLKL (p-MLKL), total
MLKL and Actin antibodies. (C) Cells collected at 120 min were subjected to IP by MLKL
antibody (MLKL-IP) or mCherry antibody (mCherry-IP) and then tested for the presence of
RIP3 and MLKL, respectively, by Western blotting using the corresponding antibodies.
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Figure 30. MLKL knocking down suppresses acidosis-induced cell death. N2a cells were
transfected with mRIP3-mCherry in combination with either a control shRNA or either of the
two MLKL shRNAs and used after 48 hrs. (A) The expression of MLKL was assessed by
Western blotting. The intensity ratios of MLKL to actin are shown at the bottom. (B) Cells were
treated with pH 7.4 or pH 6.0 ECS for 1 hr and then recovered in the normal culture medium
for 7 hrs, followed by SYTOXBLUE staining. The number of SYTOXBLUE-positive cells was
counted and the percentage to total calculated. Error bars represent SDs. *, P＜0.05. Results
are representatives of two independent experiments.
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3.3.4 pH 6.0 ECS down regulates RIP1 and IκBα in N2a cells independently of
RIP3
Besides RIP3 and MLKL, the conventional DR signaling also includes RIP1
regulation of NFκB pathway (127). To examine if acidosis-induced RIP1 activation also
affects NFκB function, I measured the levels of IκBα, whose decrease indicates NFκB
activation, in N2a cells over the time course of 1 hr pH 6.0 ECS treatment and 3 hr
recovery. For comparison, I also measured total RIP1 levels in the same cell lysates.
Interestingly, both RIP1 and IκBα were down regulated after the 1 hr treatment of pH
6.0 ECS (Figure 31B, 32A), with the decrease of IκBα occurring slightly earlier than
that of RIP1. These changes could be independent, but they could also implicate that
NFκB activation by the acid treatment turned on some genes that cause RIP1 to
decrease. Nonetheless, RIP3 appears to be dispensable for the changes found in RIP1
and IκBα since the decreases occurred in wild type N2a cells that do not express RIP3.
The expression of mCherry or RIP3-mCherry in N2a cells did not alter the effect of pH
6.0 ECS on decreasing IκBα (Figure 32B).
Interestingly, it has been reported that ASIC1 expression is important for
acidosis-induced ERK-mediated NFκB activation in tumors, and this pathway is
upregulated in some cancers to promote cell invasion and metastasis (128). I also
found ASIC1 to be critical for the acidosis-induced NFκB activation. In HEK293 cells,
which express ASIC1 but not RIP3, acidosis decreased IκBα levels similarly as in N2a
cells. In HT29 cells, which do not endogenously express ASIC1, the pH 6.0 ECS failed
to induce any change of IκBα. However, when I introduced ASIC1 into the HT29 cells,
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the IκBα level dropped in response to the pH 6.0 ECS treatment (Figure 32 C, D).
Collectively, the above data suggest that the acid-induced activation of NFκB is
dependent on ASIC1 but not RIP3, implicating a functional coupling between ASIC1
and RIP1 in the absence of RIP3.
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Figure 31. Acidosis down regulates RIP1 independently of RIP3. (A) Schematics of
experimental protocol used. Wild type N2a cells were treated with pH 7.4 or pH 6.0 ECS for 1
hr and then recovered in the normal culture medium for another 3 hrs as indicated. (B) Cell
lysates from different time points as indicated were subjected to Western blot analysis to
measure RIP1 levels. Actin was used as the loading control. (C) RIP1/actin ratios over the time
course of pH 7.4 or 6.0 ECS treatment and recovery in the normal medium for experiment
shown in (B). Results are representatives of three independent experiments.
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Figure 32. Acidosis down regulates IkBα in an ASIC1-dependent manner but
independently of RIP3. (A) The same cell lysates as that used in Figure 29 were subjected to
Western blot analysis to measure IkBα levels. Actin was used as the loading control. (B) Wild
type N2a cells or N2a cells expressing mCherry or RIP3-mCherry were treated as in (A). Cell
lysates from the 120-min time point were assessed by Western blotting for IκBα and actin,
showing no effect of mCherry or RIP3-mCherry. (C) HEK293 and HT29 cells were treated as
in (A) but only lysates from the 120-min time point were analyzed by Western blotting for IkBα
and actin. Note the decrease in IκBα in pH 6.0-treated HEK293 cells but no change in HT29
cells. (D) HT29 cells were transfected with ASIC1a-GFP and then subjected to the treatment
with pH 7.4 or pH 6.0 ECS as in (A). Only lysates from the 120-min time point were analyzed
by Western blotting for IkBα and actin. The expression of ASIC1a rescued the acidosis-induced
IκBα decrease in HT29 cells. Results (A) and (B) are representatives of three independent
experiments. Results (C) and (D) are representatives of two independent experiments.
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3.3.5 Starvation plays a critical role in acidosis-induced cell death
Acidosis by itself can cause cell death in cultured neurons, but the pH of the
medium must be very low (pH<6.2 for ~ 4 hr) or the treatment needs to be prolonged
(pH<6.6 for >6 hr) (129). The routine protocol for in vitro acidosis assay, adapted from
the literature that examined ASIC1a-dependent acidotoxic neuronal death (98, 123),
consists of inclubating cells in a pH 6.0 ECS for 1 hr, followed by replacing the
treatment solution with the normal culture medium for about 24 hrs. The ECS contains
no serum, growth factors or any amino acid, and therefore is typical of starvation
treatment routinely used to induce autophagy (130). Indeed, I found the LC3-II and
phosphor-p70S6K levels to be decreased in neurons treated for 1 hr in both pH 7.4
and pH 6.0 ECS (Figure 33), indicating that the ECS treatment induced autophagy in
our system.
To learn if the ECS treatment is necessary for the acid-induced neuronal death,
I used culture media with different pH instead of ECS to treat the neurons for 1 h and
then allowed the cells to recover in the normal (pH 7.4) culture medium for 24 hrs.
Surprisingly, there was no detectable neuronal demise in samples that had been
exposed to media with acidic pH (Figure 34A). To determine which component(s) of
the culture medium protected cells from the acid-induced death, I supplemented the
pH 6.0 ECS with 10% FBS or omitted FBS from the DMEM culture medium. The
addition of FBS into the pH 6.0 ECS fully abolished the acidosis-induced cell death in
N2a cells that expressed RIP3. The serum-free pH 6.0 DMEM, which contains amino
acids but not growth factors and other components of the FBS, on the other hand,
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moderately supported the acid-induced death, but not as severely as pH 6.0 ECS
(Figure 34B). These findings suggest that both amino acid starvation and serum
contribute to acidosis-induced cell death, with the latter being more pronounced. To
examine if starvation is only involved in acidotoxic death or if it is also required for other
acidosis-induced and ASIC1a-dependent cellular processes, I also measured the
effect of pH 6.0 culture medium (with 10% FBS) on the levels of RIP1 and IkBα over a
period of 0.5 to 4 hrs, with the first hr being pH 6.0 treated and the remaining 3 hrs for
recovery in the normal culture medium. Different from the pH 6.0 ECS treatment, RIP1
and IkBα levels did not change markedly following the treatment of pH 6.0 medium
(Figure 33), suggesting that similar to acidosis-induced death, starvation is also a
cofactor for the acid-induced degradation of RIP1 and IkBα.
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Figure 33. Treatment with ECS triggers a decrease in LC3-II levels in WT N2a cells
independent of pH. WT N2a cells were treated with pH 7.4 or pH 6.0 ECS for 1 hr and then
recovered in the normal culture medium for another 7 hrs as indicated in (A). Cell lysates from
different time points as indicated were subjected to western blot analysis for LC3 (B) and
phosphor-p70S6K and total p70S6K (C) levels, actin was used as a loading control. Results are
representatives of three independent experiments.
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Figure 34. Starvation is required for acidosis induced cell death. (A) Primary neurons were
treated for 1 hr with medium or ECS of pH 7.4 or pH 6.0 and then recovered in the normal
culture medium for 24 hrs before cell viability was assessed by CTB assay. (B) N2a cells
expressing RIP3-mCherry were incubated with indicated solutions for 1 hr and recovered in the
normal culture medium for 7 hrs. Cells were then stained with SYTOXBLUE and quantified as
percentage of SYTOXBLUE positive cells. Error bars represent SDs. NS, Not significant. *, P

＜0.05. Results are representatives of three independent experiments.
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Figure 35. The lack of effect of pH 6.0 medium on RIP1 and IkBα levels in the absence of
starvation. WT N2a cells were treated with pH 6.0 medium for 1 hr and then recovered in the
normal culture medium for 3 hrs. Cell lysates from different time points as indicated were
subjected to western blot analysis to measure the RIP1 and IkBα protein levels. Actin was used
as a loading control.
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3.3.6 Acidosis induces AIF nuclear translocation
In a recent study, it was shown that parthanatos is one of the mechanisms by
which tissue acidosis associated with ischemia augments the formation of PAR
polymers, the nuclear translocation of AIF, and neuronal cell death (118). In a separate
study it was shown that serum deprivation induces autophagy and predominantly an
AIF-dependent apoptosis in cultured hippocampal neuronal cell line HT22, where the
nuclear translocation of AIF was also observed (130). These findings prompted us to
consider the possibility that AIF nuclear translocation may be involved in our
experimental setting, in which both acidosis and starvation occurred during the 1 hr
treatment of pH 6.0 ECS. Therefore, I examined the localization of AIF in N2a cells by
immunofluorescence staining at 7 hrs after challenging the cells with ECS of different
pH for 1 hr. In control cells that expressed mCherry, AIF was localized predominantly
in the cytosol and in the perinuclear region of the cytoplasm. In N2a cells expressing
RIP3-mCherry treated with pH 6.0 ECS for 1 hr, however, there was an increased colocalization of AIF with DAPI (Figure 36A). Quantification of cells showing nuclear
staining of AIF revealed a statistically significant augmentation of AIF nuclear
translocation in N2a cells expressing RIP3-mCherry that were treated with pH 6.0 ECS
as compared to that with pH 7.4 ECS, but not in cells expressing mCherry (Figure
36B). Interestingly, I also observed a nuclear translocation of RIP3-mCherry in
response to pH 6.0 ECS, consistent with the study showing a physical interaction
between AIF and RIP3 (131). The nuclear translocation of RIP3 could also be caused
by the rupture of nuclear membrane or nuclear pore, which would allow RIP3-mCherry
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to be diffused into the nucleus.
On the other hand, I did not find any upregulation of AIF protein expression as
reported for HT22 cells that were serum deprived and underwent AIF-dependent
apoptosis (130) (Figure 36C). Importantly, I also did not detect any accumulation of
PAR following the treatment N2a cells expressing RIP3-mCherry with pH 6.0 ECS,
suggesting that the 1 hr treatment of acidosis and starvation triggered AIF release
independent of nuclear damage or at least independent of PAR production.
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Figure 36. Acidosis induces AIF and RIP3 nuclear translocation. N2a cells expressing
mCherry or RIP3-mCherry were treated with pH 7.4 or pH 6.0 ECS for 1 hr and recovered in
the normal culture medium for 7 hrs. Cells were fixed and stained with anti-AIF (green) and
DAPI (blue, for nuclei staining). Representative images taken from fluorescent microscope are
shown in (A). Scale bar: 15 μm. The percentage of cells with nuclear staining of AIF or RIP3
was quantified in (B). (C) Western blot analysis of AIF protein from cell lysates collected at
the same time points as above.
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3.3.7 ROS and MPTP are involved in AIF nuclear translocation in response to
acidosis/ starvation
In order to be translocated to the nucleus, AIF must be released from
mitochondria first. Previously, it has been showed that mitochondrial permeability
transition pore (MPTP), reactive oxygen species (ROS), calpain as well as PARP
contribute to the AIF release from mitochondria. To explore the molecular mechanism(s)
underlying acid and starvation induced AIF translocation, I tested whether or not
disrupting the above pathways could protect cells from death induced by the pH 6.0
ECS. I used inhibitors for voltage-dependent anion channels (VDAC, an essential
component of MPTP), DIDS (500 μM) and TRO19622 (20 μM); antioxidants: NAC (6
mM), TEMPOL (500 μM), and Trolox (100 μM); a calpain inhibitor: ALLN (10 μM); and
a PARP inhibitor: DPQ (30 μM). Interestingly, the pH 6.0 ECS-induced death of RIP3expressing N2a cells was suppressed by VDAC inhibitors and antioxidants but not by
inhibiting calpain or PARP (Figure 37), suggesting that MPTP and ROS are involved
in the acidosis/starvation-induced cell death, which may occur independently of
calpain-mediated cleavage and PARP activation .
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Figure 37. VDAC inhibitors and antioxidants attenuated acidosis induced cell death. (A)
Live-cell fluorescent images of SYTOXBLUE straining (green) of N2a cells expressing RIP3mCherry treated with pH 6.0 ECS in the absence (pH 6.0 only) and the presence of indicated
drugs, VDAC inhibitors: DIDS (500 μM), TRO19622 (20 μM); antioxidants: NAC (6 mM),
TEMPOL (500 μM), Trolox (100 μM); calpain inhibitor: ALLN (10 μM); Poly(ADP-ribose)
polymerase (PARP) inhibitor: DPQ (30 μM). For each condition, the fluorescence image was
merged with bright field image to show the overall cell distribution and morphology. (B)
Quantification for (A) showing the percentage of SYTOXBLUE-positive cells among the total
cells under each condition. Error bars represent SDs. NS, Not significant. *, P＜0.05. Results
are representatives of three independent experiments.
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3.3.8 RIP3 inhibitor dabrafenib attenuated ischemic brain damage in vivo
The above in vitro data demonstrate that RIP3 and its downstream signaling
molecules including MLKL and AIF contribute to acidosis and starvation induced cell
death through ASIC1a and RIP1. Given that acidotoxicity is an important contributor of
brain damage associated with ischemic stroke, it is anticipated that targeting one or
more of the key contributors of the acidosis-induced necroptotic pathway will protect
neurons from injury during or following ischemic stroke. Among the key contributors to
acidosis-induced death, blocking ASIC1a with PcTX1, inhibiting RIP1 with Nec1,
disrupting VDAC with its inhibitors, and using antioxidants to sequester ROS have all
been shown to be neuroprotective in the stroke models (98, 111, 132, 133). However,
whether or not inhibiting RIP3 with its antagonists, e.g. dabrafenib, an FDA approved
drug, would also be neuroprotective was not known. Therefore, we examined the
possible protection effect of dabrafenib for the first time in the mouse model of cerebral
ischemia, in which ischemia was induced by MCAO. Dabrafenib 2.5 μg (0.5 μg/μl x 5
μl), was intracerebroventricularly (i.c.v.) injected 30 min after 1-hr MCAO. Comparing
to mice injected with vehicle or nothing, Dabrafenib significantly decreased the infarct
volumes as assessed by TTC staining (Figure 38). Similar decrease was also
achieved by ASIC1a gene knockout. Thus, our in vivo data indicate that inhibiting RIP3
by dabrafenib may be of therapeutic value for neuroprotection in ischemic stroke, just
like that previously shown for antioxidants, and RIP1 and VDAC inhibitors.
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Figure 38. Neuroprotection by RIP3 inhibitor dabrafenib and ASIC1a gene knock out. (A)
Scheme of middle cerebral artery occlusion (MCAO) treatment and assay protocol. Mouse
brain slices after 1 hr of MCAO treatment followed by 24 hr reperfusion were collected for
TTC staining. Dabrafenib, 2.5 μg (0.5 μg/μl x 5 μl), was intracerebroventricularly (i.c.v.)
injected at 30 min after the start of reperfusion. (B) TTC-stained brain sections showing infarct
areas in the ischemic brains from WT mice, WT mice injected with vehicle or dabrafenib, and
ASIC1a KO mice. (C) Summary data for B showing the ratio of infarct volumes to contralateral
area in each condition. Error bars represent SDs for n number of animals tested. * p < 0.05, vs.
WT; # p < 0.05, vs. WT+Vehicle.
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3.4 Summary and discussion
Necroptosis has been shown to play an important role in ischemic brain injury.
Our recent work showed that an ASIC1a-RIP1 interaction induced by acidosis is
important for the activation of necroptosis in brain neurons in response to ischemic
stroke (110). In this study, I identified serum starvation as a critical contributing factor
for acidosis-induced cell death. I provide evidence that RIP3 is also required for
acidosis/starvation induced necroptosis. Inhibiting RIP3 reduced both acid-induced
death of cultured mouse cortical neurons in vitro and brain infarction in mice subject to
MCAO in vivo. I showed that there are at least two key downstream molecules of RIP3
that are involved in acidosis/starvation-induced cell death: MLKL and AIF.
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Figure 39. Schematic working model. Under ischemic conditions, the coincident occurrence
of acidosis and starvation triggers the interaction of ASIC1a and RIP1, which subsequently
causes phosphorylation of RIP3 and MLKL. The formation of RIP1/RIP3/MLKL necrosome
induces necroptosis. At the same time, AIF is translocated from mitochondria to the nucleus
and contributes to neuronal death.

3.4.1 Starvation is a critical contributing factor for acidosis induced cell death
My data indicate that starvation is crucial for acidosis-induced cell death as in
the presence of 10% FBS, the low pH treatment (1 h pH 6.0) with either medium or
ECS did not induce cell death. This is consistent with previous findings that only severe
or prolonged acidification could kill the neurons (129). I found an increase in autophagy
as indicated by the decrease in pS6K levels during the 1-h ECS treatment.
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Autophagy has a dual role as an intrinsic cell-death mechanism under some
circumstances and as a cell-survival pathway under others. Autophagy is commonly
induced by TNFR1-triggered necroptosis. However, it was thought that autophagy is a
cellular response to necroptosis, rather than a part of the death execution mechanism
per se (111). The process of autophagy and its role in acidosis-induced cell death need
to be further investigated. Inhibition of autophagy by pharmacologic or genetic
interventions should be used to test the contribution of autophagy in acidosis/starvation
induced cell death in later experiments.
Under ischemic stroke conditions in vivo, there should be a combination of
acidosis and starvation since the blood supply to neurons was blocked. Indeed, studies
using both ASIC1 blocker (98) and autophagy inhibitor 3-MA (131) have shown
protective effect of these drugs in rodent model of ischemic stroke.

3.4.2 RIP3 and MLKL are involved in acidosis/starvation-induced cell death
Classic necroptosis induced by death receptors requires the formation of
RIP1/RIP3/MLKL necrosome (134). It is not a surprise that acidosis/starvation-induced
cell death also requires RIP3 and MLKL since we have demonstrated that RIP1 can
bind to AISC1a upon acidification and become phosphorylated. Given that caspase 8
inhibition is required for necroptosis and acidosis was reported to reduce neuronal
apoptosis(135), the acidosis/starvation conditions would favor necroptosis rather than
apoptosis. Our data indicate ASIC1a may represent a new DR to trigger necroptosis
under acidosis
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Due to the lack of a suitable antibody, changes in the total protein level of
endogenous RIP3 could not be tested in the cultured neurons in this study. However,
in N2a cells heterologously expressing RIP3, I did not find any change in the expressed
RIP3 in response to pH 6.0 ECS, although it was reported that RIP3 levels were
upregulated in hippocampal neurons under ischemic insults in one study (136). The
time

course

of

the

changes

(expression,

phosphorylation,

interaction)

of

RIP1/RIP3/MLKL warrants further evaluation both in vitro and in vivo since it may
provide time window for therapeutic intervention of ischemic stroke.
Interestingly, some recent studies showed that both RIP1 and RIP3 are involved
in autophagy regulation, with RIP1 negatively regulating basal autophagic flux (137)
while RIP3 positively regulating autophagy (138). These suggest that there are cross
talks between necroptosis and autophagy.

3.4.3 AIF translocation in acidosis/starvation induced cell death
Our results also indicate that AIF nuclear translocation contributes to
acidosis/starvation-induced cell death, occurring downstream of RIP3. AIF is a protein
essential for life due to its critical role as a mitochondrial oxidoreductase. However,
once it has arrived in the nucleus, AIF could organize a DNA-degrading complex to
cause caspase-independent chromatinolysis and cell death (139).
AIF is imbedded into the inner mitochondrial membrane. Its release from
mitochondria usually requires a proteolytic cleavage. Two major elements take part in
the AIF proteolytic process: (i) two families of cysteine proteases: calpains and
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cathepsins; (ii) the activation of pro-apoptotic molecules from the Bcl-2 family, such as
Bax or Bid, to facilitate the mitochondrial outer membrane permeabilization (139).
Caspases can trigger the permeabilization of the outer mitochondrial membrane,
thereby triggering the release of cytochrome c and/or AIF in apoptosis (140). There
are also caspases-independent AIF release. One example is parthanatos, in which
PARP-1 is a key regulator (117).
Although RIP1 plays a critical role in both parthanatos and TNFR1-induced
necroptosis, the latter cannot be blocked by inhibition of calpains and PARP-1 or by
downregulation of AIF. Inhibiting calpain or PARP-1 also failed to suppress
acidosis/starvation-induced cell death, in which AIF translocation was found. However,
other features of parthanatos like PAR accumulation is not found in our experiments.
These suggest that acidosis/starvation-induced cell death is not parthanatos but
necroptosis that requires the participation of AIF. Thus acidosis shares some
mechanisms of parthanatos and TNFR-1 mediated necroptosis.
How is AIF released from mitochondria under acidosis/starvation is not clear.
Our data demonstrate that VDAC and ROS are two important factors. It is reasonable
that VDAC serves as an important component of MPTP, which facilitates the release
of AIF. Recently, it was described that VDAC can be cleaved and subsequent bind to
Bax; these two molecules form a sufficiently large passage for the release of AIF (141).
Although a previous study showed that AIF was increased in response to serum
deprivation to mediate AIF-dependent apoptosis in HT22 neurons (130), I did not find
any upregulation in AIF protein expression in our system. Although my preliminary data
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suggest that there was no cleavage of AIF in acidosis/starvation-induced cell death,
this possibility needs more careful examination in future experiments.

3.4.4 Contribution of mitochondria in acidosis/starvation-induced necroptosis
There are some debates on whether or not mitochondria play an essential role
in necroptosis. Contrary to the initial belief, the lethal activity of RIP3 kinase is not
influenced by the absence of mitochondrial protein phosphatase phosphoglycerate
mutase family member 5 (PGAM5) and dynamin 1 like (DNM1L, best known as
dynamin-related protein 1, DRP1) (142).
It has been suggested that enhanced metabolism accompanied by increased
ROS production is probably responsible in part for the function of RIP3 in mediating
necrosis (143). Although there are some papers showing that antioxidant failed to
protect neuronal cell death (98, 111, 123), I found that some antioxidants had protective
effect on acidosis/starvation-induced death. Some of these drugs have been
previously shown to be neuroprotective against ischemic insults (132, 133). However,
further experiments should monitor the mitochondrial status and ROS generation
during acidosis/starvation-induced cell death, especially since ASIC1a was reported to
localize also in mitochondria (144).

3.4.5 Acidosis/starvation-induced necroptosis and stress adaption
Cells subjected to perturbations of homeostasis almost invariably mount a
tightly coordinated response aimed at (i) the removal of the initiating stimulus (when
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possible), (ii) the repair of molecular and/or organelle damage, and (iii) eventually, the
re-establishment of physiological conditions. When these objectives cannot be
attained, cells generally undergo RCD as a means to preserve the homeostasis of the
whole organism (1). In our system of acidosis/starvation, we also found mobilization of
some RCD inhibitory signals such as NFκB activation and autophagy. The activation
of NFκB and autophagy is usually considered as pro-survival, implicating that cells may
also try to fight back to the perturbations of intracellular homeostasis caused by the pH
6.0 ECS as a way of stress adaptation. The death, however, happened drastically to
most of the cells after the withdrawal of pH 6.0 ECS and during the re-supply of normal
medium. Indeed, during the ischemia/reperfusion process in an injured brain, it is the
later reperfusion phase when necroptosis occurred. During this reperfusion phase,
both RCD-inhibitory and RCD-promoting signals may coexist and counteract with each
other. Thus, it is highly possible that these signals can be modified to change the final
outcome of the RCD, especially with the better understanding of the key components
and their interactions.
Here, I defined some of the signaling pathways of the ASIC1a-RIP1 triggered
necroptosis. Elucidating the signaling pathway can also help identify better points of
intervention for therapeutic targeting. For example, inhibiting RIP3 rather than others
may have its own benefits. First, the crucial physiological function mediated by ASIC1a
and RIP1 will be maintained, particularly the decreased IκBα indicating activation of
NFκB in response to acidic and starvation stress may be beneficial for cell survival via
turning on gene expression to fight with the stress; Second, RIP3 may have multiple
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downstream targets that contribute to cell death, such as VDAC, ROS, and MLKL.
Perturbation of them singly may not be sufficient to fully block the cell death triggered
by the stress.
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Chapter 4

Discussion
In this thesis, I showed clear evidence and some of the molecular mechanisms
for PD-1 inhibition of RCD triggered by NK cells in the immune system and RIP3–
mediated RCD in neurons in the nervous system. Both will shed lights on a better
understanding of RCD and ways to interrupt of signal steps to either block PD-1 to
promote NK cytotoxicity or inhibit RIP3 to protect neurons from dying. These studies
also have broader perspectives because the molecules I have studied have multiple
functions in different systems. PD-1 is not restricted to the immune system; it also plays
important roles in the nervous system. RIP3 is not only involved in the nervous system;
it also contributes importantly to immune response.
PD-1 and PD-L1 are functional in the nervous system and they are changeable
under certain conditions. PD-L1 is constitutively expressed in nonlymphoid organs,
such as heart, lung, pancreas and brain, and has been implicated in the maintenance
of peripheral tolerance involving these tissues (145). The levels of PD-1/PD-L1 in
primary human macrophages, brain endothelial cells (hBECs), microglia, and neurons
were reported to be increased after exposure to methamphetamine (METH). The
moderate levels of endogenous PD-1/PD-L1 in astrocytes were diminished by METH
exposure, suggesting that a PD-1/PD-L1 interplay in these cell types could orchestrate
the intercellular interactive communication for neuronal death or protection in the brain
environment (146). PD-1 is expressed in large retinal ganglion cells (RGC) and is
upregulated after optic nerve crush. PD-1 positive large RGCs do not express cleaved
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caspase-3 after optic nerve injury (147). PD-1 mediates signaling pathway in
developmental programmed cell death (PCD) during postnatal RGC maturation (148).
In contrast to PD-1 signaling, which is indubitable an immune suppresser. There
are some controversial reports about RIP1/RIP3-mediated necroptosis in cancer. RIP3
and MLKL are reported to participate in chemotherapy-induced tumor immunogenic
cell death (ICD). The failure to induce necroptosis is coupled to a lack of immune
infiltration of the tumors post-chemotherapy, as well as to the failure of tumor growth
reduction (149). RIP3-deficient mice are more susceptible to infection by a number of
pathogenic viruses (150, 151), supporting the idea that necroptosis can restrain viral
infection. However, it is reported that the necrosome promotes pancreatic oncogenesis
via immune suppression(152).
Thus, expanding our understanding on molecular signaling in RCD in one
system would help to understand its function in other systems and different
pathological conditions. There are usually multiple contributors to cell death under any
given pathophysiological situation.
However, there are still many unanswered questions about the detailed
molecular mechanisms of RCD. For examples, how does PD-1 affect the ILK
polarization, how does calcium affect the LG polarization, whether PD-1 affects the
distribution of LFA 1 and activating receptors? And with respect to necroptosis, what is
the time course of changes (expression, phosphorylation, interaction) of RIP1, RIP3
and MLKL in acidosis-induced cell death and ischemic brain, how does AIF get
released from mitochondria, does mitochondria damage contribute to the acidosis
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induced necroptosis, does ASIC1a translocate to in mitochondria in response to
acidosis and then play a role in this process, how does ASIC1a and many other DRs
contribute to brain injury in ischemia? Addressing these questions would help provide
more complete elucidation of signaling pathways associated with PD-1 in NK cells and
that associated with ASIC1 and RIP3 in neurons and offer new clues towards
development of novel therapeutic strategies for cancer and neuroprotection in
ischemic stroke.
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